alpha-aminopyridine has been researched along with buparlisib in 226 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 182 (80.53) | 24.3611 |
| 2020's | 44 (19.47) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, DL; Briggs, KJ; Buonamici, S; Dorsch, M; Fordjour, P; García-Echeverría, C; Green, J; Guo, R; Hsiao, K; Kelleher, JF; Lengauer, C; Maira, SM; Monahan, JE; Morrissey, M; Ospina, B; Ostrom, L; Pan, S; Peukert, S; Sellers, WR; Vattay, A; Wang, A; Warmuth, M; Watkins, DN; Williams, J; Wu, X; Yao, YM; Yu, Q; Yuan, J | 1 |
| Crowder, RJ; Ellis, MJ; Gao, F; Guintoli, T; Lin, L; Ma, CX; Phommaly, C; Sanchez, CG | 1 |
| Fu, J; Garcia-Echevrria, C; Kim, YW; Koul, D; LaFortune, TA; Liu, JL; Maira, SM; Ramnarian, D; Shen, R; Tiao, N; Wang, S; Yuan, Y; Yung, WK | 1 |
| Bang, YJ; Han, SW; Im, SA; Kim, TY; Oh, DY; Park, E; Park, J | 1 |
| Clarke, PA; Workman, P | 1 |
| Baselga, J; Bendell, JC; Birle, D; Burris, HA; De Buck, SS; de Jonge, M; Demanse, D; Goldbrunner, M; Peters, M; Rodon, J; Ru, QC; Verweij, J | 1 |
| Brachmann, S; Burger, M; Chène, P; De Pover, A; Dorsch, M; Fabbro, D; Fritsch, C; García-Echeverría, C; Guthy, D; Hofmann, F; Huang, A; Knapp, M; Maira, SM; Martiny-Baron, G; Menezes, D; Nagel, T; Pecchi, S; Schlegel, R; Schnell, C; Sellers, WR; Shoemaker, K; Sterker, D; Voliva, CF; Wiesmann, M; Wilson, CJ | 1 |
| Baladandayuthapani, V; He, J; Hong, S; Kwak, LW; Lan, Y; Li, H; Lin, H; Liu, Z; Lu, Y; Qian, J; Shah, J; Thomas, S; Yang, J; Yi, Q; Zhang, L; Zheng, Y | 1 |
| Buckley, AF; Cho, YJ; Eroshkin, A; Febbo, PG; Korshunov, A; McLendon, RE; Miller, CR; Moore, CE; Northcott, PA; Pei, Y; Pfister, SM; Read, TA; Schmitt, EM; Sun, JL; Taylor, MD; Tewari, AK; Wang, J; Wechsler-Reya, RJ; Westbrook, TF; Witt, H | 1 |
| Bachmann, E; Galle, PR; Khillimberger, K; Linnig, M; Moehler, M; Mueller, A; Schimanski, CC | 1 |
| Bergling, S; Blommers, MJ; Brachmann, SM; Brümmendorf, T; Fritsch, C; Garcia-Echeverria, C; Gaulis, S; Guthy, DA; Hattenberger, M; Henry, C; Hofmann, F; Kauffmann, A; Kazic-Legueux, M; Kleylein-Sohn, J; Laborde, L; Maira, SM; Murakami, M; Romanet, V; Sellers, WR; Stauffer, F; Sterker, D; Vaxelaire, J; Wilson, C | 1 |
| Hussien, K; Kelly, CJ; Muschel, RJ | 1 |
| Lee, M; Pellegata, NS; Reubi, JC; Waser, B | 1 |
| Chen, M; Khuri, FR; Owonikoko, TK; Ramalingam, SS; Ren, H; Sun, SY; Tao, H; Yue, P | 1 |
| Aloyz, R; Amrein, L; Grenier, J; Panasci, L; Shawi, M | 1 |
| Gao, X; Jia, S; Lee, SH; Loda, M; Maira, SM; Roberts, TM; Signoretti, S; Stack, EC; Wu, X; Zhao, JJ | 1 |
| Beaven, A; Dave, SS; Fan, A; Jima, DD; Liu, Q; Love, C; McKinney, MS; Patel, A; Smith, J; Walsh, K | 1 |
| de Gramont, A; Dos Santos, C; Faivre, S; Raymond, E; Riveiro, ME; Serova, M; Slimane, K; Tijeras-Raballand, A | 1 |
| Boukouris, AE; Buitrago-Molina, LE; Hegermann, J; Kirstein, MM; Kühnel, F; Manns, MP; Marhenke, S; Orlik, J; Pothiraju, D; Schütt, J; Vogel, A | 1 |
| Chen, M; Deng, X; Khuri, FR; Li, Y; Owonikoko, TK; Ren, H; Sun, SY; Yue, P; Zhao, L | 1 |
| Antón, P; Arribas, J; Baselga, J; Eichhorn, PJ; García-García, C; Hahn, WC; Ibrahim, YH; Kim, SY; Marlow, S; Parra, JL; Pérez-Garcia, J; Prat, A; Prudkin, L; Rodríguez, O; Sánchez, G; Scaltriti, M; Serra, V | 1 |
| Coordes, A; Eucker, J; Lenarz, M; Liu, H; Possinger, K; Scholz, CW; Zang, C | 1 |
| Chen, X; Hao, M; Liu, J; Mao, Y; Shen, K; Shen, Y; Sun, X; Wang, J; Zhao, M; Zu, L | 1 |
| Aymerich, M; Campo, E; Colomer, D; López-Guerra, M; Montraveta, A; Pérez-Galán, P; Rosich, L; Roué, G; Saborit-Villarroya, I; Villamor, N; Xargay-Torrent, S | 1 |
| Bassi, C; Dowling, RJ; Gorrini, C; Ho, J; Mak, TW; Miller, SJ; Neel, BG; Raught, B; Srikumar, T; Stambolic, V | 1 |
| Geisthoff, UW; Hess, D; Nguyen, HL | 1 |
| Beroukhim, R; Buonamici, S; Chung, J; Dabral, SK; Dorsch, M; Filbin, MG; Franchetti, Y; Kelleher, JF; Kung, AL; Ligon, KL; Pak, E; Pazyra-Murphy, MF; Ramkissoon, S; Redjal, N; Segal, RA; Shulman, DS; Sun, Y; Tabak, B; Theisen, MA; Wang, Q; Zhao, J | 1 |
| Wang, Q; Weisberg, E; Zhao, JJ | 1 |
| Badura, S; Falkenburg, JH; Liebermann, M; Nijmeijer, BA; Ottmann, OG; Pfeifer, H; Ruthardt, M; Tesanovic, T; Wystub, S | 1 |
| Cao, L; Davis, S; Helman, LJ; Kang, Z; Meltzer, PS; Walker, R; Yu, Y; Zhu, YJ | 1 |
| Antunes, IL; Barata, JT; Bertaina, A; Buontempo, F; Chiarini, F; Locatelli, F; Lonetti, A; Martelli, AM; McCubrey, JA; Melchionda, F; Orsini, E; Pagliaro, P; Pession, A; Ricci, F; Tazzari, PL | 1 |
| Liang, YC; Liu, Q; Liu, T; Shi, LL; Wu, G; Wu, HG; Xue, HJ | 1 |
| Ando, Y; Doi, T; Inada-Inoue, M; Kakizume, T; Mitsuma, A; Ohtsu, A; Quadt, C; Robson, M; Sato, M; Suenaga, N; Yoshino, T | 1 |
| Anthony, L; Campbell, K; Elliott, VA; Evers, BM; Harris, JW; Kim, JT; Li, J; Mustain, WC; Song, J; Townsend, CM; Valentino, JD; Wang, C; Weiss, H; Zaytseva, YY | 1 |
| Arteaga, CL; Chanthaphaychith, S; Dahlman, K; Rexer, BN | 1 |
| Dicker, AP; Feo, N; Lawrence, YR; Leiby, B; Liu, Y; Rice, B; Wachsberger, PR | 1 |
| Borger, D; Bradford, LS; Clark, RM; Foster, R; Groeneweg, JW; Growdon, WB; Rauh-Hain, A; Rueda, BR; Zhang, L; Zukerberg, LR | 1 |
| Herrera Loeza, SG; Kamande, JW; Moffitt, RA; Soper, SA; Tignanelli, CJ; Torphy, RJ; Yeh, JJ | 1 |
| Ashton, TM; Fokas, E; Hussien, K; Kannan, P; Kelly, CJ; Muschel, RJ; Pearson, N; Shipley, RJ; Stratford, M | 1 |
| Bendell, JC; Braña, I; De Jonge, MJ; Di Tomaso, E; Eskens, F; Homji, N; Massacesi, C; Mills, D; Rodon, J; Sarr, C; Siu, LL; Trandafir, L | 1 |
| Abramson, VG; Arteaga, CL; Balko, JM; Cantley, LC; Forero, A; Isakoff, SJ; Kuba, MG; Li, Y; Mayer, IA; Sanders, ME; Van den Abbeele, AD; Winer, E; Yap, JT | 1 |
| Liu, B; Peng, D; Wu, Y; Zhou, Y | 1 |
| Foster, KA; Jane, EP; Morales, A; Pollack, IF; Premkumar, DR | 2 |
| Antonakos, B; Cooke, VG; Danial, NN; Flemming, D; Hurov, KE; Jones, MD; Korn, JM; Ledell, J; Lehár, J; Mishina, Y; Schoumacher, M; Sellers, WR; Shao, W; Sonkin, D; Steiger, J; Stump, MD; Yan-Neale, Y | 1 |
| Balsas, P; Campo, E; Casserras, T; Colomer, D; Giné, E; Kalko, SG; López-Guillermo, A; Matas-Céspedes, A; Pérez-Galán, P; Rodriguez, V; Rosich, L; Roué, G; Vidal-Crespo, A; Villamor, N | 1 |
| Elbast, W; Heudi, O; Kretz, O; Lanshoeft, C; Leuthold, LA; Picard, F; Schlotterbeck, G | 1 |
| Dedes, KJ; Fink, D; Gutsche, K; Imesch, P; Samartzis, EP; Stucki, M | 1 |
| Cheng, AL; Cheng, JC; Gao, M; Hsu, FM; Liu, WL; Tsai, CL; Tzen, KY | 1 |
| Azab, AK; Azab, F; Ghobrial, IM; Glavey, SV; Manier, S; Mishima, Y; Moschetta, M; Roccaro, AM; Sacco, A; Sahin, I; Tsang, B; Zhang, Y | 1 |
| Dan, S; Kong, D; Yamazaki, K; Yamori, T | 1 |
| Aymerich, M; Beà, S; Campo, E; Colomer, D; López-Guerra, M; Montraveta, A; Pérez-Galán, P; Roldán, J; Rosich, L; Roué, G; Salaverria, I; Xargay-Torrent, S | 1 |
| Alagesan, B; Bardeesy, N; Benes, CH; Contino, G; Corcoran, RB; Deshpande, V; Engelman, J; Guimaraes, AR; Hezel, AF; Loda, M; Weissleder, R; Wojtkiewicz, GR; Wong, KK | 1 |
| Abramson, V; Arteaga, CL; Balko, JM; Estrada, MV; Fox, EM; Garrett, JT; González-Angulo, AM; Kelley, MC; Kuba, MG; Mayer, IA; Meszoely, IM; Mills, GB; Red-Brewer, M; Rizzo, M; Schwarz, LJ | 1 |
| Bedard, PL; Britten, CD; Carter, K; Csonka, D; Demanse, D; Janku, F; Le, N; Nauwelaerts, H; Paz-Ares, L; Pérez-García, J; Peters, M; Sessa, C; Stathis, A; Tabernero, J; Van Cutsem, E; Vansteenkiste, J; Wainberg, ZA; Zubel, A | 1 |
| Du, J; Liu, Q; Ni, Y; Pang, Z; Wang, L; Zhang, J | 1 |
| Lattanzio, L; Lo Nigro, C; Merlano, M; Milano, G; Monteverde, M; Russi, E; Tonissi, F; Vivenza, D | 1 |
| Fitter, S; Gan, ZY; Martin, SK; To, LB; Zannettino, AC | 1 |
| Huang, Q; Liu, S; Pan, H; Xia, J; Yuan, Y | 1 |
| Aversa, C; Geuna, E; Martinello, R; Milani, A; Montemurro, F; Scaltriti, M; Valabrega, G | 1 |
| Bialer, P; Carvajal, RD; Fury, MG; Gerecitano, JF; Ho, AL; Hyman, DM; Iasonos, A; Katabi, N; Konner, J; Lacouture, ME; Monson, KR; Snyder, AE; Spriggs, DR; Stasi, MA; Teitcher, JB; Voss, MH; Winkelmann, JL | 1 |
| Harrington, M | 1 |
| Choi, HJ; Choi, JW; Jang, KS; Kang, JH; Kim, HY; Kim, S; Kong, G; Lee, JY; Oh, SH; Oh, YH; Park, JH; Shin, DH; Son, T; Won, HY; Woo, JK; Yi, K | 1 |
| Chen, H; Chen, Z; Dong, H; Huang, C; Li, G; Li, X; Luo, D; Sun, L; Sun, S; Wei, S; Yang, H; Zhou, Y | 1 |
| Dawood, S; Rastogi, S; Sirohi, B | 1 |
| Alfieri, RR; Ardizzoni, A; Bonelli, MA; Caffarra, C; Cavazzoni, A; Cretella, D; Falco, A; Frati, C; Fumarola, C; Galetti, M; La Monica, S; Lagrasta, CA; Madeddu, D; Petronini, PG; Quaini, F; Rossetti, P; Saccani, F; Tiseo, M | 1 |
| Adetchessi, T; Barlier, A; Chinot, O; Defilles, C; Dufour, H; Enjalbert, A; Figarella-Branger, D; Fuentes, S; Germanetti, AL; Graillon, T; Lisbonis, C; Metellus, P; Mohamed, A; Roche, PH | 1 |
| Aimone, P; Canon, JL; De Braud, F; De Pas, T; Di Tomaso, E; Dy, GK; Felip, E; Gray, JE; Gridelli, C; Grossi, F; Reck, M; Roussou, P; Soria, JC; Su, WC; Thongprasert, S; Vansteenkiste, JF; Vidam, GA; Wang, YA; Yoshioka, H | 1 |
| Csonka, D; Duval, V; Hazell, K; Kobalava, ZD; Lorenzo, S; Trandafir, L; Waldron, E | 1 |
| Costa, FF; Favaro, P; Lopes, MR; Machado-Neto, JA; Morini, BC; Pereira, JK; Saad, ST; Traina, F | 1 |
| Blanco, B; Del Cañizo, MC; Herrero-Sánchez, C; Rodríguez-Serrano, C; Sánchez-Barba, M | 1 |
| Choi, JH; Chung, YY; Jung, IH; Lim, GL; Park, SW; Park, YN | 1 |
| Akiyama, R; Anderson, JL; Denny, CT; Federman, N; Park, A; Tap, WD | 1 |
| Carlson, C; Ivanova, A; McRee, AJ; O'Neil, BH; Sanoff, HK | 1 |
| Estévez, LG; García, E; Hidalgo, M | 1 |
| Bari, A; Civallero, M; Cosenza, M; Ferri, P; Pozzi, S; Sacchi, S | 1 |
| Ademuyiwa, F; Ellis, MJ; Griffith, M; Griffith, OL; Guo, Z; Han, J; Hoog, J; Lockhart, C; Luo, J; Ma, CX; Mardis, E; Nagaraj, G; Naughton, M; Pluard, T; Ramu, A; Skidmore, ZL; Spies, NC; Suresh, R; Thomas, S; Trani, L | 1 |
| Amaria, R; Bassett, RL; Bernatchez, C; Bosenberg, MW; Cascone, T; Chen, G; Chen, JQ; Chen, PL; Cooper, ZA; Creasy, C; Davies, MA; Deng, W; Forget, MA; Gajewski, TF; Gershenwald, JE; Glitza, IC; Haymaker, C; Heffernan, TP; Hu, J; Hwu, P; Kwong, LN; Lazar, AJ; Li, HS; Liang, X; Liu, C; Lizée, G; Malu, S; Mbofung, R; McKenzie, JA; McQuade, JL; Overwijk, WW; Peng, W; Radvanyi, L; Roszik, J; Spranger, S; Tetzlaff, MT; Tieu, TN; Torres-Cabala, CA; Wargo, JA; Williams, LJ; Woodman, SE; Xu, C; Yu, X; Zhang, C | 1 |
| Guo, R; Hu, Y; Ji, W; Liu, J; Wei, J; Zhang, J; Zhi, X; Zhou, Y | 1 |
| Allegretti, M; Amadori, S; Bertolini, F; Foà, R; Licchetta, R; Mirabilii, S; Orecchioni, S; Reggiani, F; Ricciardi, MR; Tafuri, A; Talarico, G; Torrisi, MR | 1 |
| Hong, S; Jang, HH; Kang, M; Kim, HY; Kim, S; Lee, WS | 1 |
| Hu, Y; Zhang, J; Zhang, M; Zhou, Y | 1 |
| Behera, P; Chiocca, EA; Cho, CF; Lawler, SE; Nowicki, MO; Speranza, MC | 1 |
| Bian, X; Cheng, H; Jiang, N; Liu, P; Roberts, TM; Wang, D; Wang, M; Wang, X; Zhang, Y; Zhao, JJ | 1 |
| Chen, Y; Huang, G; Liao, L; Mao, X; Tang, Q; Wang, W; Wu, R | 1 |
| Alcaraz, M; Bao, L; Cho, YJ; Crawford, J; Durden, DL; Garlich, JR; Joshi, S; Levy, ML; Malicki, D; Messer, K; Morales, GA; Newbury, R; Singh, AR; Zulcic, M | 1 |
| Al-Awar, R; Babichev, Y; Boutros, PC; Datti, A; Dickson, BC; Gladdy, RA; Isaac, M; Kabaroff, L; Prakesch, M; Sun, RX; Uehling, D; Venier, R | 1 |
| Auger, C; Chanal, M; Chevallier, P; Fonteneau, G; Honnorat, J; Jouanneau, E; Lucia, K; Monteserin Garcia, JL; Rachwan, A; Raverot, G; Raverot, V; Theodoropoulou, M; Trouillas, J | 1 |
| Byers, LA; Cardnell, RJ; Diao, L; Fan, Y; Feng, Y; Heymach, JV; Masrorpour, F; Mukherjee, S; Nilsson, M; Shen, Y; Stewart, CA; Tong, P; Wang, J | 1 |
| Fan, XX; He, J; He, JX; Huang, J; Huang, L; Jiang, ZB; Leung, EL; Li, N; Li, X; Liu, L; Pan, H; Xie, C; Xie, Y; Yao, XJ | 1 |
| Bai, J; Guo, R; Hu, Y; Yu, F; Zhang, H; Zhang, J; Zhang, S; Zhao, J; Zhou, Y | 1 |
| de Gruijl, TD; de Haas, RR; Huijts, CM; Quiles Del Rey, M; Santegoets, SJ; van der Vliet, HJ; Verheul, HM | 1 |
| Bellmunt, J; Choueiri, TK; De Velasco, G; Harshman, L; Hirsch, M; McDermott, DF; McKay, RR; Rosenberg, JE; Signoretti, S; Sweeney, C; Vaishampayan, U; Van Allen, EM; Walsh, M; Werner, L | 1 |
| Alexander, BM; Claus, EB; Du, R; Goel, S; Guo, H; Hayashi, M; Iglehart, JD; Kang, YJ; Krop, IE; Ligon, AH; Ligon, KL; Lin, NU; Luu, V; Marco, E; Nguyen, QD; Ni, J; Ramkissoon, LA; Ramkissoon, SH; Roberts, TM; Stover, DG; Wang, ZC; Winer, EP; Xie, S; Yuan, GC; Zhao, JJ | 1 |
| Enger, PØ; Førde, HE; Goplen, D; Leiss, L; Miletic, H; Netland, IA; Rahman, MA; Skeie, BS; Sleire, L | 1 |
| Chang, J; Qiu, Z; Wang, G; Yue, S | 1 |
| Gray, JW | 1 |
| Asara, JM; Bellinger, G; Cantley, LC; Daly, MB; Hok, RC; Hu, H; Juvekar, A; Kim, B; Lien, EC; Lyssiotis, CA; Scully, R; Seth, P; Son, J; Ullas, S; Wulf, GM; Yadegarynia, S | 1 |
| Cheng, H; Jiang, N; Li, C; Li, T; Liu, P; Roberts, TM; Wang, D; Wang, M; Xiang, L; Zhang, Y; Zhao, JJ | 1 |
| Chen, Y; Tong, J; Wang, Y; Wu, Y; Xiang, R; Xu, W; Yan, H; Yu, W; Zhang, N | 1 |
| Bozec, A; Chamorey, E; Ebran, N; Gautier, M; Marcie, S; Milano, G; Penault-Llorca, F; Radosevic-Robin, N; Yahia, HB | 1 |
| Chen, S; Ma, WJ; Wu, XZ; Zhang, HR; Zhang, JH; Zhang, WL | 1 |
| Chen, M; Chen, T; Feng, J; Gao, L; Guo, H; Liang, Y; Liu, F; Liu, JJ; Ren, H; Shang, D; Shi, P; Thakur, A; Wang, T; Xu, F; Yang, T; Zhang, S | 1 |
| Bashash, D; Bayati, S; Delshad, M; Ghaffari, SH; Nooshinfar, E; Safaroghli-Azar, A | 1 |
| Dhanasingh, I; Kanteti, R; Kindler, HL; Lennon, FE; Mambetsariev, B; Mirzapoiazova, T; Riehm, JJ; Salgia, R | 1 |
| Liu, P; Xu, B; Zhang, C | 1 |
| Andreeff, M; Borthakur, G; Burger, J; Cortes, J; Daver, N; DeBose, L; DiNardo, CD; Garcia-Manero, G; Jabbour, E; Kantarjian, H; Konopleva, M; Kornblau, S; Pemmaraju, N; Ragon, BK; Ravandi, F; Schneider, H; Wierda, W; Zeng, Z | 1 |
| Almeida, J; Blanco, B; Corchete, LA; Del Cañizo, C; García-Briñón, J; Herrero-Sánchez, MC; Inogés, S; Rodríguez-Serrano, C; San Miguel, JF; San Segundo, L; Santos-Briz, Á | 1 |
| Dong, T; Duval, V; Hazell, K; Trandafir, L; Wu, YL; Xu, B; Zhang, LI | 1 |
| Batista López, N; Beck, JT; Campone, M; Chan, A; Delaloge, S; Di Tomaso, E; Dirix, L; Goteti, S; Hegg, R; Khan, QJ; Krivorotko, P; Manikhas, A; Martín, M; Massacesi, C; O'Shaughnessy, J; Ramos Vázquez, M; Ruiz Borrego, M; Shtivelband, M; Urban, P | 1 |
| Bekaii-Saab, T; Bloomston, M; Che, Z; Elnaggar, O; Farren, MR; Farris, AB; Guttridge, DC; Lesinski, GB; Mace, TA; Maskarinec, JM; Rajasekera, P; Talbert, EE; Timmers, CD; Yang, J; Young, GS | 1 |
| Chau, NG; Haddad, RI; Tishler, RB | 1 |
| Aghajanian, C; Barry, WT; Bell-McGuinn, KM; Berger, MF; Birrer, M; Cantley, LC; Farooq, S; Hok, RC; Liu, H; Liu, J; Luo, W; Matulonis, UA; Mills, GB; Obermayer, E; Palakurthi, S; Solit, DB; Spagnoletti, T; Taylor, BS; Westin, SN; Whalen, C; Winer, E; Won, H; Wulf, GM | 1 |
| Chaire, V; Fourneaux, B; Italiano, A; Karanian, M; Laroche-Clary, A; Lucchesi, C; Pineau, R | 1 |
| Ju, W; Kim, CY; Kim, HJ; Kim, SC; Kim, YH; Lee, SY | 1 |
| Arnaud, A; Berton-Rigaud, D; Fabbro, M; Favier, L; Floquet, A; Foa, C; Heudel, PE; Joly, F; Kalbacher, E; Kaminsky, MC; Lesoin, A; Lortholary, A; Meunier, J; Priou, F; Ray-Coquard, I; Roche-Forestier, S; Roemer-Becuwe, C; Selle, F; Tazi, Y; Treilleux, I; You, B | 1 |
| Beijersbergen, RL; Bernards, R; Halonen, P; Leite de Oliveira, R; Lieftink, C; Šuštić, T; van de Ven, M; van den Heuvel, MM; van der Heijden, MS; Wang, L | 1 |
| Bonazzi, VF; Cummings, MC; Geng, X; Ju, RJ; Mahon, CE; Packer, LM; Pollock, PM; Stephenson, SA | 1 |
| Amin, AR; Anisuzzaman, AS; Chen, Z; Chen, ZG; Haque, A; Rahman, MA; Shin, DM; Wang, D; Zhang, C | 1 |
| Aimone, P; Alyasova, A; Barone, C; Chakravartty, A; Chol, M; Dechaphunkul, A; Erfán, J; Faivre, S; Hirawat, S; Karpenko, A; Kasper, S; Kim, SB; Kiss, LA; Li, SH; Licitra, L; Lin, JC; Mesía, R; Nagarkar, R; Ochsenreither, S; Remenár, É; Soulières, D; Tamás, L; Turri, S | 1 |
| Worden, FP | 1 |
| Aher, A; Akhmanova, A; Bargsten, K; Beaufils, F; Bohnacker, T; Burke, JE; Cmiljanovic, N; Cmiljanovic, V; Díaz, JF; Fabbro, D; Inglis, AJ; Melone, A; Prota, AE; Rageot, D; Sele, AM; Steinmetz, MO; Williams, RL; Wymann, MP; Zvelebil, M | 1 |
| Abida, W; Bialer, P; Drilon, A; Erinjeri, JP; Fury, MG; Gerecitano, JF; Gounder, M; Harding, JJ; Ho, AL; Hyman, DM; Iasonos, A; Iyer, G; Jhaveri, K; Katabi, N; Lacouture, ME; Li, BT; Makker, V; Monson, KR; Razavi, P; Smyth, LM; Teitcher, JB; Voss, MH | 1 |
| Castellano, D; Chakravartty, A; Chi, KN; Csonka, D; de Bono, J; Dirix, L; Fizazi, K; Gravis, G; Machiels, JP; Maier, J; Massard, C; Mellado, B; Mita, A; Turri, S | 1 |
| Alumkal, JJ; Armstrong, AJ; Beer, TM; Bitting, RL; George, DJ; Halabi, S; Healy, P; Hobbs, C; Kephart, J; Mundy, K; Slottke, R; Soleau, CF; Winters, C; Yu, EY | 1 |
| Arteaga, CL; Awada, A; Baselga, J; Campone, M; Chia, S; Clemons, M; Cortés, J; De Laurentiis, M; Dharan, B; Di Tomaso, E; Hachemi, S; Hurvitz, S; Im, SA; Ito, Y; Iwata, H; Jagiełło-Gruszfeld, A; Jiang, Z; Jonat, W; Massacesi, C; Masuda, N; Pistilli, B; Takahashi, M; Tseng, LM; Urban, P; Vuylsteke, P | 1 |
| Bond, J; Durston, M; Hall, J; Kelly, S; Nagulapally, AB; Saulnier Sholler, G; VanSickle, E; Voydanoff, A; Zhao, P | 1 |
| Chen, S; Huang, TT; Liu, CY; Petrossian, K; Tseng, LM; Wu, CY | 1 |
| Beaufils, F; Bohnacker, T; Borsari, C; Cmiljanovic, N; Cmiljanovic, V; Fabbro, D; Giese, B; Hebeisen, P; Hillmann, P; Jackson, E; Marone, R; Melone, A; Mestan, J; Rageot, D; Sele, A; Williams, RL; Wymann, MP; Zhang, X; Zvelebil, M | 1 |
| Bashash, D; Delshad, M; Ghaffari, SH; Momeny, M; Safa, M; Safaroghli-Azar, A | 1 |
| Chen, B; Kraus, D; Palasuberniam, P | 1 |
| Dees, EC; Henderson, GE; Reeder-Hayes, KE; Roberts, MC | 1 |
| Chen, IC; Cheng, AL; Hsiao, LP; Huang, IW; Lin, CH; Lu, YS; Wei-Wu Chen, T; Yeh, LC; Yu, HC | 1 |
| Baselga, J; Bermejo, B; de la Pena, L; Denkert, C; Gombos, A; Kümmel, S; Lee, SC; Loi, S; Loibl, S; Lux, M; Michiels, S; Nekljudova, V; Piccart, MJ; Rezai, M; Steger, G; Turri, S; Untch, M; Urban, P; Von Minckwitz, G; Zardavas, D | 1 |
| Bian, X; Cheng, H; Gao, J; Liu, P; Luo, F; Roberts, TM; Rui, C; Wang, D; Wang, Y; Zhao, JJ; Zheng, T | 1 |
| Cho, BC; Choi, HM; Hong, MH; Joo, HS; Kang, HN; Kim, DH; Kim, HR; Lee, Y; Yoon, SO; Yun, MR | 1 |
| Autret, A; Bertucci, F; Boher, JM; Camerlo, J; Campone, M; Charafe-Jauffret, E; Extra, JM; Gonçalves, A; Guerin, M; Hervieu, A; Isambert, N; Lokiec, F; Pakradouni, J; Provansal, M; Rezai, K; Sabatier, R; Viens, P | 1 |
| Barca, EG; Barrigon, DC; Bociek, RG; Gerecitano, J; Kim, WS; Kong, O; Martinelli, G; Pisal, CB; Salles, G; Tavorath, R; Turgut, M; Younes, A | 1 |
| Bang, JH; Bang, YJ; Jin, L; Jin, MH; Nam, AR; Oh, DY; Park, JE | 1 |
| Anders, CK; Carey, LA; Dees, EC; Hu, Z; Kornblum, ZA; Marcom, PK; McRee, AJ; Moore, DT; Perou, CM; Phipps, R; Reeder-Hayes, K; Weck, KE; Zamboni, WC | 1 |
| Augereau, P; Berton Rigaud, D; Bourbouloux, E; Campone, M; Frenel, JS; Gourmelon, C; Patsouris, A; Robert, M | 1 |
| Brotherton, R; Chang, ALS; Moffat, A; Pague, A; Tran, DC; Zhu, GA | 1 |
| Bachelot, T; Chan, S; Farci, D; Han, HS; Jerusalem, G; Kong, A; Massacesi, C; Mouhaër, SL; Pistilli, B; Pluard, T; Robinson, D; Saura, C; Tomaso, ED; Urban, P; Urruticoechea, A | 1 |
| Bachelot, T; Blau, S; Bordonaro, R; Ciruelos, E; Csőszi, T; Decker, T; Dharan, B; Di Leo, A; Egle, D; El-Hashimy, M; Janni, W; Johnston, S; Kalev, D; Lee, KS; Lønning, PE; Mouret-Reynier, MA; O'Regan, R; Schirone, A; Sellami, D; Tjan-Heijnen, VCG; Weber, D | 1 |
| Chen, M; Chen, Y; Deng, WG; Guo, W; Jiang, W; Li, L; Li, Y; Li, Z; Liao, Y; Xu, X; Yu, W; Zhang, Z; Zhao, X; Zou, K; Zou, L | 1 |
| Chumduri, C; Daniel, PT; Gillissen, B; Müller, A; Richter, A; Scholz, CW | 1 |
| Ding, Y; Hu, G; Huang, Y; Liu, S; Wang, J; Wei, W; Yang, G; Yang, L; Zhou, L | 1 |
| Beijnen, JH; Buil, LCM; Çitirikkaya, CH; de Gooijer, MC; Thota, N; van Tellingen, O; Zhang, P | 1 |
| Auriemma, RS; Cappabianca, P; Cavallo, LM; Colao, A; De Martino, MC; Di Cera, M; Frio, F; Grasso, LFS; Patalano, R; Pivonello, C; Pivonello, R; Solari, D; Vitulli, F | 1 |
| Atis, S; Combès, E; Del Rio, M; Gabanou, M; Gongora, C; Jarlier, M; Larbouret, C; Martineau, P; Mollevi, C; Pérez-Gracia, E; Torro, A; Tosi, D; Vié, N | 1 |
| Benisvy, D; Borson-Chazot, F; Bournaud, C; Dantony, E; de la Fouchardière, C; Decaussin-Petrucci, M; Delahaye, A; Do Cao, C; Eberle, MC; Illouz, F; Klein, M; Lapras, V; Lasolle, H; Leboulleux, S; Lopez, J; Niccoli, P; Rabilloud, M; Schlumberger, M; Tabarin, A; Wassermann, J | 1 |
| Arteaga, CL; Awada, A; Baselga, J; Bourdeau, L; Campone, M; Chia, S; Clemons, M; Cortés, J; De Laurentiis, M; El-Hashimy, M; Hurvitz, S; Im, SA; Ito, Y; Iwata, H; Jagiełło-Gruszfeld, A; Jiang, Z; Jonat, W; Le Mouhaër, S; Masuda, N; Pistilli, B; Sankaran, B; Sellami, D; Tseng, LM | 1 |
| De Martino, D; Di Cristofano, A; Orlacchio, A; Ranieri, M; Yilmaz, E; Zhao, K | 1 |
| Huang, P; Liu, X; Wu, H; Zhang, F | 1 |
| Hu, Y; Yang, Q; Zhang, J; Zhao, H | 1 |
| Bashash, D; Delshad, M; Momeny, M; Pourbagheri-Sigaroodi, A; Riyahi, N; Safaroghli-Azar, A | 1 |
| Balkenhol, M; Beißbarth, T; Blazquez, R; Bleckmann, A; Evert, M; Hanisch, UK; Korf, U; Perera-Bel, J; Proescholdt, M; Pukrop, T; Reinz, E; Riemenschneider, MJ; Ritter, U; Salinas, G; Schatlo, B; Schildhaus, HU; Schulz, M; Seitz, S; Siam, L; Stadelmann, C; Utpatel, K; Vollmer, E; Wachter, A; Wiemann, S; Wlochowitz, D; Wolff, A | 1 |
| Bashash, D; Kazemi, A; Momeny, M; Pourbagheri-Sigaroodi, A; Safaroghli-Azar, A | 1 |
| Batchelor, TT; Grommes, C; Nayak, L; Tun, HW | 1 |
| Wang, H; You, G; Zhang, J | 1 |
| Bavelloni, A; Blalock, W; Cocco, L; Faenza, I; Focaccia, E; Orsini, A; Piazzi, M; Ramazzotti, G | 1 |
| Chen, IC; Lu, YS; Yang, MH | 1 |
| Huang, P; Li, Q; Liu, X; Tong, D; Wu, H; Zhang, F | 1 |
| Bukum, N; Hofman, J; Morell, A; Novotna, E; Wsol, V | 1 |
| Agar, NYR; Alexander, BM; Basu, SS; Batchelor, TT; Beroukhim, R; Brown, LE; Chang, SM; Chi, AS; Cloughesy, TF; Colman, H; de Groot, JF; DeAngelis, LM; Dunn, IF; Gaffey, SC; Gilbert, MR; Haidar, S; Heath, JR; Horky, LL; Huse, JT; Kim, J; Koul, D; Kuhn, JG; Lee, EQ; Ligon, AH; Ligon, KL; Martinez-Ledesma, JE; McCluskey, CS; Mellinghoff, IK; Nayak, L; Omuro, AM; Park, MA; Pelton, K; Prados, MD; Ramkissoon, S; Reardon, DA; Rinne, ML; Roberts, TM; Touat, M; Wei, W; Wen, PY; Wu, S; Young, GS; Yung, WKA; Zhao, JJ | 1 |
| Algazi, AP; Daud, A; Munster, PN; Ortiz-Urda, S; Pelayo, A; Posch, C; Rotow, J | 1 |
| DuRoss, AN; Eaton, CT; Landry, MR; Neufeld, MJ; Rosch, JG; Sahay, G; Sun, C; Thomas, CR | 1 |
| Bao, X; Lu, S; Niu, X; Wang, M; Wang, Q; Wang, S; Wang, Y; Xu, L; Zhang, J | 1 |
| Ahn, KS; Go, J; Han, H; Hong, J; Kim, D; Koh, Y; Liu, J; Park, H; Park, J; Shin, DY; Yoon, SS | 1 |
| Bradley, KM; Campo, L; Fenwick, JD; Gleeson, FV; Green, M; Higgins, GS; Horne, A; Macpherson, RE; Maughan, TS; McCole, MG; McGowan, DR; McKenna, WG; Mohammed, S; Muschel, RJ; Ng, SM; Panakis, N; Prevo, R; Skwarski, M; Strauss, VY; Stuart, R; Tacconi, EMC; Vallis, KA | 1 |
| Bharathy, S; Chuah, C; Dong, T; Durrant, ST; Gisslinger, H; Guglielmelli, P; Lavie, D; le Coutre, P; Lopez, JM; Maffioli, M; Nagler, A; Wroclawska, M | 1 |
| Arao, Y; Kida, JI; Kitanaka, A; Kurozumi, N; Nakahara, T; Sakakibara, K; Suemori, SI; Tohyama, K; Tsujioka, T | 1 |
| Becker, KP; Burris, HA; Chowdhary, SA; Eakle, JF; Hainsworth, JD; Langdon, RM; Mekhail, T; Padula, GDA; Scarberry, M; Shaifer, CA; Shastry, M; Shih, K; West-Osterfield, K; Wright, D; Yost, KJ | 1 |
| Bardia, A; Bedard, PL; Evans, H; Gounder, M; Janku, F; Lolkema, MP; LoRusso, P; Maacke, H; Rodon, J; Schuler, M; Sessa, C; Stephenson, JJ; Sun, Y; Tan, DSW; Thomas, M | 1 |
| Higgins, GS; McGowan, DR; Skwarski, M | 1 |
| van Dam, PA | 1 |
| Aasen, SN; Bjerkvig, R; Feng, Z; Hoang, T; Knappskog, S; Parajuli, H; Roy, K; Stokke, K; Thorsen, F; Wang, J | 1 |
| Arshad, S; Brisson, RJ; Dekker, A; DeSouza, JA; Kochanny, S; Saloura, V; Seiwert, TY; Vokes, EE | 1 |
| Bohemier, C; Cabanero, M; Chen, E; Goodwin, R; Jonker, D; Kennecke, H; Lim, H; Ritter, H; Seymour, L; Tsao, MS; Tu, D; Vickers, M | 1 |
| Alipour, F; Bashash, D; Riyahi, N; Safaroghli-Azar, A; Sari, S; Zandi, Z | 1 |
| Aan de Kerk, DJ; Beijersbergen, RL; Jansen, MH; Kuijpers, TW; Lieftink, C; Morris, B; Tuijnenburg, P; van Leeuwen, EMM | 1 |
| Andonova, T; Bersani, C; Dalianis, T; Holzhauser, S; Kostopoulou, ON; Lange, BKA; Ohmayer, A; Wickström, M | 1 |
| Lu, H; Luo, Q; Wang, Y; Zhou, X | 1 |
| Eismann, J; Gray, KP; Heng, YJ; Konstantinopoulos, PA; Matulonis, UA; Murphy, CJ; Nabavi, S; Vlachos, IS; Waldschmidt, JM; Wulf, GM | 1 |
| Azaro, A; Balbin, OA; Cheng, Y; De Vos, F; Joerger, M; Kirsilae, T; Lassman, AB; Rodon, J; Sepulveda, J; Tabatabai, G; Tiedt, R; van den Bent, M; Vicente, S; Wen, PY; Wick, W; Yung, WKA; Zhang, H; Zhao, S | 1 |
| Akce, M; Alese, OB; Bilen, MA; Carthon, B; Chen, Z; Collins, H; El-Rayes, BF; Harris, WB; Harvey, RD; Khuri, FR; Kudchagkar, RR; Lawson, DH; Lewis, C; Lonial, S; Owonikoko, TK; Ramalingam, SS; Shaib, WL; Sica, GL; Steuer, CE; Wu, C; Zhang, C | 1 |
| Brenner, JC; Heft Neal, ME; Jiang, H; Leonard, E; Mann, JE; McHugh, JB; Michmerhuizen, NL; Owen, JH; Prince, MEP; Wang, J; Zhai, J | 1 |
| Bashash, D; Hamidpour, M; Safaroghli-Azar, A; Shiri Heris, R; Yousefi, AM | 1 |
| Chen, G; Fang, L; Hao, N; Meng, Y; Ming, M; Wang, J; Yu, L | 1 |
| Aimone, P; Benson, C; Brandt, U; Doi, T; Gelderblom, H; George, S; Hertle, S; Jones, RL; Le Cesne, A; Leahy, M; Renouf, DJ; Schӧffski, P; Valverde Morales, C | 1 |
| Aloyz, R; Amrein, L; Assouline, S; Banerji, V; Caplan, S; Chen, BE; Hagerman, L; Hasegawa, W; Hay, AE; Owen, C; Panasci, L; Peters, A; Prica, A; Robinson, S; Rodriguez, L; Shivakumar, S; Skamene, T | 1 |
| Bashash, D; Esmaeili, S; Pourbagheri-Sigaroodi, A; Sadeghi, S; Safaroghli-Azar, A | 1 |
| Byeon, HK; Cho, BC; Choi, JW; Hong, MH; Jung, I; Kang, HN; Kim, DH; Kim, HR; Kim, J; Kim, JH; Koh, YW; Lee, H; Lim, SM; Paik, S; Park, AY; Park, YM; Pyo, KH; Shin, EJ; Yoon, SO; Yun, MR | 1 |
| Andersen, D; Dickson, A; Edwards, J; Holmes, E; Leung, HY; Markert, E; McAllister, MJ; McCall, P; Underwood, MA | 1 |
| Afghani, S; Ai, WZ; Balassanian, R; Bandyopadhyay, S; Gao, HX; Gill, R; McCormick, F; Moasser, M; Pincus, L; Rakhshandehroo, T; Rubenstein, J; Wang, L; Wu, CH; Yang, CY | 1 |
| Beck, JT; DeGroot, J; Donnet, V; El-Hashimy, M; Mason, W; Mills, D; Rodon, JA; Rosenthal, M; Wen, PY | 1 |
| Campone, M; Chinot, O; Clement, PM; DeGroot, J; Donnet, V; El-Hashimy, M; Gan, H; Gil-Gil, MJ; Idbaih, A; Mason, W; Mills, D; Pineda, E; Raizer, J; Rosenthal, M; Wen, PY | 1 |
| Chang, YC; Chao, TY; Chen, SC; Chitapanarux, I; Gao, M; Jung, KH; Kim, JH; Lee, KS; Liu, CT; Lu, YS; Park, YH; Shotelersuk, K; Slader, C; Sohn, J; Tseng, LM; Valenti, R; Yang, Y | 1 |
| Al-Ahmadie, H; Bajorin, DF; Berger, MF; Bhayankara, A; Boyd, ME; Farooki, A; Garcia-Grossman, IR; Iyer, G; Kim, PH; McCoy, AS; McPherson, V; Milowsky, MI; Ostrovnaya, I; Reardon, B; Regazzi, AM; Rosenberg, JE; Roth, AJ; Scott, SN; Solit, DB; Van Allen, E | 1 |
| Abdelhady, AM; Bachelot, T; Calvo, E; Fasolo, A; Forero-Torres, A; Hamilton, E; Im, YH; Lee, SC; Lu, YS; Maur, M; Nardi, L; Ruan, S; Stammberger, U; Tiedt, R; Tolaney, SM | 1 |
| Bauer, RJ; Beckhove, P; Brockhoff, G; Eichberger, J; Ettl, T; Fiedler, M; Hautmann, M; Menevse, AN; Piendl, G; Reichert, TE; Schulz, D | 1 |
| Ahn, MJ; Cho, BC; Choi, EC; Choi, JW; Hong, MH; Ju, KY; Jung, DM; Kang, HN; Kim, HR; Kim, HS; Kim, J; Kim, KR; Kim, SH; Kim, TM; Koh, YW; Paik, S; Pyo, KH; Shim, HS; Sun, JM; Yoo, J; Yoon, SO; Yun, MR | 1 |
| Chera, B; Lenze, N; Sheth, S | 1 |
| Arteaga, CL; Barroso-Sousa, R; Bermejo, B; Cantley, LC; Céliz, P; Ciruelos, E; Garrido-Castro, AC; Gavilá, J; Guo, H; Krop, IE; Li, Y; Lin, NU; Mills, GB; Paré, L; Prat, A; Rodon, J; Saura, C; Savoie, J; Serra, V; Solit, DB; Villagrasa, P; Winer, EP; Xu, Z | 1 |
| Clark, AS; DeMichele, A; Makhlin, I | 1 |
| Ge, Y; He, G; Li, H; Wang, J; Wang, S; Xu, Y; Zhu, Q | 1 |
| Jian, L; Lian, S; Liu, M; Liu, N; Wang, S; Zhang, G; Zhang, Y; Zhao, Q | 1 |
| Chen, JH; Chuang, FC; Hwang, TZ; Su, YC; Wang, CC; Yeh, SA | 1 |
| Chen, L; Li, Y; Wang, S; Wang, X; Wang, Y; Zhang, W | 1 |
| Bilbao, D; Camarena, V; Kesmodel, SB; Mustafi, S; Qureshi, R; Sant, DW; Slingerland, J; Wang, G; Wilkes, Z | 1 |
| Beck, AC; Cho, E; Franke, C; Gosse, M; Gu, VW; Koch, KE; Kulak, MV; Landers, SR; Li, T; Paemka, L; Pamatmat, AJ; Thompson, DT; Weigel, RJ; White, JR; Wu, VT | 1 |
| Bashash, D; Mehrpouri, M; Momeny, M | 1 |
| Elkabets, M; Kong, D; Li, X; Liu, H; Liu, Y; Peng, X; Wang, R; Wang, W; Zhang, S; Zhao, B; Zhong, Y | 1 |
| Akamatsu, H; Arteaga, CL; Brewer, MR; Brown, BP; Chatterjee, S; Hanker, AB; He, J; Jayanthan, HS; Koch, JP; Lalani, AS; Lee, KM; Lin, CC; Marín, A; Meiler, J; Servetto, A; Sheehan, JH; Sudhan, DR; Ye, D | 1 |
| Gong, ML; Qu, GP; Shi, M; Wang, D; Wang, P; Wu, JH; Zhang, ZJ | 1 |
| Batlevi, CL; De Frank, S; Drullinsky, P; Gerecitano, JF; Hamilton, A; Hamlin, PA; Horwitz, SM; Kumar, A; Matasar, MJ; Michaud, L; Moskowitz, A; Moskowitz, CH; Nakajima, R; Nichols, C; Rademaker, J; Salles, G; Schöder, H; Seshan, V; Stewart, CM; Straus, D; Tsui, DWY; Whiting, K; Younes, A; Zelenetz, AD | 1 |
| Chen, ZS; Claret, FX; Elkabets, M; Jiao, W; Kong, D; Peng, X; Wang, F; Wang, R; Yang, Y; Zhang, S; Zhong, Y; Zhong, Z | 1 |
| Tulsawani, R; Vohora, D; Vyas, P | 1 |
| Bueno, AC; da Silva Júnior, RMP; de Castro, M; Martins, CS; Oliveira, HA; Pugliesi, RS | 1 |
| Alinari, L; Baiocchi, RA; Benson, D; Blum, KA; Bond, DA; Christian, BA; Cohen, JB; Huang, Y; Jaglowski, S; Maddocks, KJ | 1 |
| Al-Ali, R; Ameziane, N; Bauer, P; Junghanss, C; Kong, W; Krake, S; Lerch, MM; Ma, Y; Murua Escobar, H; Parveen, A; Radefeldt, M; Sekora, A; Sender, S; Weiss, FU; Zechner, D | 1 |
| Hwang, Y; Kim, HC; Shin, EJ | 1 |
| Doi, T; Hara, H; Kato, K; Kojima, T; Muro, K; Nishina, T; Nomura, S; Ohtsu, A; Sato, A; Takahashi, S; Wakabayashi, M | 1 |
| Grommes, C; Kaley, T; Mellinghoff, IK; Nolan, CP; Panageas, KS; Pentsova, E; Reiner, AS; Schaff, LR | 1 |
8 review(s) available for alpha-aminopyridine and buparlisib
| Article | Year |
|---|---|
Buparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancer.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Molecular Targeted Therapy; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Signal Transduction | 2015 |
Buparlisib in breast cancer.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Evaluation, Preclinical; Female; Humans; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases; Treatment Outcome | 2015 |
Inhibiting the PI3K signaling pathway: buparlisib as a new targeted option in breast carcinoma.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Mice; Molecular Targeted Therapy; Morpholines; Phosphatidylinositol 3-Kinases; Signal Transduction | 2016 |
Treatment for the endocrine resistant breast cancer: Current options and future perspectives.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Estradiol; Everolimus; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Morpholines; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction | 2017 |
Introduction of novel agents in the treatment of primary CNS lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aminopyridines; Antineoplastic Agents, Immunological; Burkitt Lymphoma; Central Nervous System Neoplasms; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Rituximab; Salvage Therapy; Thalidomide; Toll-Like Receptors; TOR Serine-Threonine Kinases; Tumor Escape | 2019 |
The efficacy and safety of neoadjuvant buparlisib for breast cancer: A meta-analysis of randomized controlled studies.
Topics: Aminopyridines; Breast Neoplasms; Humans; Morpholines; Neoadjuvant Therapy; Phosphoinositide-3 Kinase Inhibitors; Randomized Controlled Trials as Topic; Receptor, ErbB-2 | 2019 |
An evaluation of buparlisib for the treatment of head and neck squamous cell carcinoma.
Topics: Aminopyridines; Class I Phosphatidylinositol 3-Kinases; Head and Neck Neoplasms; Humans; Maximum Tolerated Dose; Morpholines; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Squamous Cell Carcinoma of Head and Neck | 2021 |
Which Is the Most Appropriate PI3K Inhibitor for Breast Cancer Patients with or without PIK3CA Status Mutant? A Systematic Review and Network Meta-Analysis.
Topics: Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Clinical Trials as Topic; Female; Humans; Morpholines; Mutation; Network Meta-Analysis; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Progression-Free Survival; Signal Transduction; Thiazoles; Treatment Outcome | 2020 |
48 trial(s) available for alpha-aminopyridine and buparlisib
| Article | Year |
|---|---|
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors | 2012 |
Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Agents; Area Under Curve; Carcinoma, Squamous Cell; Colorectal Neoplasms; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Japan; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Treatment Outcome; Young Adult | 2014 |
Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aminopyridines; Biomarkers, Tumor; Class I Phosphatidylinositol 3-Kinases; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; PTEN Phosphohydrolase | 2014 |
Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorodeoxyglucose F18; Humans; Letrozole; Middle Aged; Morpholines; Multimodal Imaging; Nitriles; Phosphoinositide-3 Kinase Inhibitors; Positron-Emission Tomography; Protein Kinase Inhibitors; Radiopharmaceuticals; Receptor, ErbB-2; Receptors, Estrogen; Tomography, X-Ray Computed; Triazoles | 2014 |
LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer.
Topics: Amino Acid Substitution; Aminopyridines; Animals; Breast Neoplasms; Dasatinib; Drug Resistance, Neoplasm; Drug Synergism; Estrogen Receptor Modulators; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Morpholines; Mutation, Missense; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Receptors, Estrogen; src Homology Domains; src-Family Kinases; Thiazoles; Xenograft Model Antitumor Assays | 2014 |
A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Neoplasms; Pyridones; Pyrimidinones | 2015 |
Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Neoplasms; Paclitaxel; Phosphoinositide-3 Kinase Inhibitors; Polyethylene Glycols; Recombinant Proteins; Treatment Outcome; Young Adult | 2015 |
Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study.
Topics: Aged; Aminopyridines; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Morpholines; Neoplasm Metastasis; Phosphatidylinositol 3-Kinases | 2015 |
A phase-1, open-label, single-dose study of the pharmacokinetics of buparlisib in subjects with mild to severe hepatic impairment.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aminopyridines; Antineoplastic Agents; Case-Control Studies; Female; Humans; Liver Diseases; Male; Middle Aged; Morpholines; Severity of Illness Index; Young Adult | 2016 |
A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors.
Topics: Administration, Oral; Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Fluorouracil; Humans; Leucovorin; Leukopenia; Male; Middle Aged; Morpholines; Nausea; Neoplasms; Organoplatinum Compounds; Phosphoinositide-3 Kinase Inhibitors | 2015 |
A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Molecular Targeted Therapy; Morpholines; Neoplasm Metastasis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2016 |
Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents; Disease-Free Survival; Humans; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Middle Aged; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2017 |
Phase I Study of the Pan-PI3K Inhibitor Buparlisib in Adult Chinese Patients with Advanced Solid Tumors.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Agents; China; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Morpholines; Neoplasms; Phosphoinositide-3 Kinase Inhibitors | 2016 |
A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4).
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Morpholines; Paclitaxel; Phosphoinositide-3 Kinase Inhibitors; Proportional Hazards Models; Receptor, ErbB-2; Treatment Outcome; Young Adult | 2017 |
Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer.
Topics: Adult; Aged; Aminopyridines; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Dose-Response Relationship, Drug; Female; Germ-Line Mutation; Humans; Middle Aged; Morpholines; Neoplasm Grading; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases | 2017 |
Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group.
Topics: Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; Disease Progression; Endometrial Neoplasms; Female; Humans; Middle Aged; Morpholines; Neoplasm Recurrence, Local; Phosphoinositide-3 Kinase Inhibitors; Recurrence; Treatment Outcome | 2017 |
Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Double-Blind Method; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; International Agencies; Male; Middle Aged; Morpholines; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Platinum; Prognosis; Survival Rate | 2017 |
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Neoplasms; Paclitaxel; Phosphoinositide-3 Kinase Inhibitors; Prognosis; PTEN Phosphohydrolase; Tissue Distribution | 2017 |
Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Asthenia; Chills; Diarrhea; Fever; Humans; Hyperglycemia; Imidazoles; Kallikreins; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quinolines; Stomatitis; Vomiting | 2017 |
Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Humans; Male; Middle Aged; Morpholines; Nitriles; Phenylthiohydantoin; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors | 2017 |
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Alanine Transaminase; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Biomarkers, Tumor; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Disease-Free Survival; DNA Mutational Analysis; DNA, Neoplasm; Double-Blind Method; Drug Eruptions; Estradiol; Exanthema; Female; Fulvestrant; Humans; Hyperglycemia; Middle Aged; Morpholines; Neoplasm Metastasis; Phosphatidylinositol 3-Kinases; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Response Evaluation Criteria in Solid Tumors; Retreatment; Signal Transduction; Survival Rate | 2017 |
Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE).
Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Australia; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Class I Phosphatidylinositol 3-Kinases; Double-Blind Method; Early Termination of Clinical Trials; Europe; Female; Humans; Ki-67 Antigen; Lymphocytes, Tumor-Infiltrating; Middle Aged; Morpholines; Mutation; Neoadjuvant Therapy; Paclitaxel; Protein Kinase Inhibitors; Receptor, ErbB-2; Time Factors; Trastuzumab; Treatment Outcome | 2017 |
PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer.
Topics: Administration, Oral; Adult; Aged; Aminopyridines; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Drug Dosage Calculations; Drug Resistance, Neoplasm; Female; France; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Morpholines; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2017 |
Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Female; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Recurrence; Remission Induction; Salvage Therapy | 2017 |
A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer.
Topics: Adult; Aminopyridines; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Maximum Tolerated Dose; Middle Aged; Morpholines; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Treatment Outcome | 2018 |
Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms; Capecitabine; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Maximum Tolerated Dose; Middle Aged; Morpholines; Receptor, ErbB-2; Response Evaluation Criteria in Solid Tumors; Trastuzumab | 2018 |
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease Progression; Disease-Free Survival; Double-Blind Method; Estradiol; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Middle Aged; Morpholines; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Time Factors; TOR Serine-Threonine Kinases; Treatment Outcome | 2018 |
Effect of Buparlisib, a Pan-Class I PI3K Inhibitor, in Refractory Follicular and Poorly Differentiated Thyroid Cancer.
Topics: Adenocarcinoma, Follicular; Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents; Disease Progression; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Pilot Projects; Progression-Free Survival; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Outcome | 2018 |
Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Female; Fulvestrant; Humans; Middle Aged; Morpholines; Postmenopause; Survival Analysis | 2018 |
Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Disease Progression; Enzyme Activation; Female; Glioblastoma; Humans; Male; Middle Aged; Morpholines; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Progression-Free Survival; Time Factors | 2019 |
Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma.
Topics: Adenocarcinoma of Lung; Aged; Aminopyridines; Anorexia; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Fatigue; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Misonidazole; Morpholines; Nausea; Phosphoinositide-3 Kinase Inhibitors; Positron Emission Tomography Computed Tomography; Radiation-Sensitizing Agents; Radiotherapy; Tumor Hypoxia | 2019 |
Results from HARMONY: an open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Nitriles; Primary Myelofibrosis; Prognosis; Pyrazoles; Pyrimidines; Tissue Distribution | 2019 |
Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II).
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Neoplasm Recurrence, Local; Neoplasms; Phosphatidylinositol 3-Kinases; Prognosis; Salvage Therapy; Survival Rate | 2019 |
Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Female; Humans; Male; Middle Aged; Morpholines; Protein Kinase Inhibitors; Response Evaluation Criteria in Solid Tumors | 2020 |
A pilot study of the pan-class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer.
Topics: Aged; Aminopyridines; Antineoplastic Agents, Immunological; Cetuximab; Drug Therapy, Combination; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Morpholines; Neoplasm Recurrence, Local; Pilot Projects; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2019 |
A phase Ib study of a PI3Kinase inhibitor BKM120 in combination with panitumumab in patients with KRAS wild-type advanced colorectal cancer.
Topics: Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorectal Neoplasms; Exanthema; Fatigue; Female; Humans; Male; Middle Aged; Morpholines; Mucositis; Panitumumab; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase | 2020 |
A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Female; Follow-Up Studies; Glioblastoma; Humans; Imidazoles; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Neoplasm Recurrence, Local; Prognosis; Proto-Oncogene Proteins c-met; PTEN Phosphohydrolase; Tissue Distribution; Triazines | 2020 |
A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Everolimus; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Neoplasms; Prognosis; Survival Rate; Tissue Distribution | 2020 |
Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Mental Disorders; Middle Aged; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Sunitinib | 2020 |
IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia.
Topics: Aminopyridines; Biomarkers; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Regulatory-Associated Protein of mTOR; Ribosomal Protein S6 Kinases, 70-kDa | 2020 |
Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Female; Glioblastoma; Humans; Male; Middle Aged; Morpholines; Phosphatidylinositol 3-Kinases; Temozolomide | 2020 |
Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Carboplatin; Female; Glioblastoma; Humans; Lomustine; Male; Middle Aged; Morpholines; Phosphatidylinositol 3-Kinases; Recurrence | 2020 |
A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma.
Topics: Aged; Aged, 80 and over; Aminopyridines; Cell Line, Tumor; Female; Humans; Male; Middle Aged; Morpholines; Neoplasm Metastasis; Phosphatidylinositol 3-Kinase; Urologic Neoplasms | 2020 |
Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Checkpoints; Cell Survival; Cetuximab; DNA Copy Number Variations; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Head and Neck Neoplasms; Humans; Male; Mice; Mice, Nude; Mice, SCID; Middle Aged; Morpholines; Mutation; Neoplasm Transplantation; Progression-Free Survival; Reproducibility of Results; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome; Up-Regulation; Whole Genome Sequencing | 2020 |
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Class I Phosphatidylinositol 3-Kinases; Disease Progression; Female; High-Throughput Nucleotide Sequencing; Humans; Middle Aged; Morpholines; Neoplasm Metastasis; Patient Safety; Protein Kinase Inhibitors; Proteomics; Response Evaluation Criteria in Solid Tumors; Survival Rate; Treatment Outcome; Triple Negative Breast Neoplasms | 2020 |
Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring.
Topics: Adenine; Adult; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Cell-Free Nucleic Acids; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Morpholines; Phosphatidylinositol 3-Kinases; Piperidines; Pyrazoles; Pyrimidines | 2022 |
A phase I study of rituximab and buparlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Humans; Lymphoma, Non-Hodgkin; Morpholines; Rituximab | 2022 |
Phase II study of BKM120 in patients with advanced esophageal squamous cell carcinoma (EPOC1303).
Topics: Aminopyridines; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Morpholines; Phosphatidylinositol 3-Kinases | 2022 |
170 other study(ies) available for alpha-aminopyridine and buparlisib
| Article | Year |
|---|---|
Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma.
Topics: Aminopyridines; Animals; Cell Proliferation; Drug Resistance, Neoplasm; Gene Amplification; Hedgehog Proteins; Insulin-Like Growth Factor I; Kruppel-Like Transcription Factors; Medulloblastoma; Mice; Morpholines; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Receptors, G-Protein-Coupled; Signal Transduction; Smoothened Receptor; Tumor Suppressor Protein p53; Up-Regulation; Zinc Finger Protein Gli2 | 2010 |
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
Topics: Aminopyridines; Antineoplastic Agents, Hormonal; Apoptosis; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Estradiol; Estrogens; Everolimus; Female; Fulvestrant; Humans; Imidazoles; Morpholines; Mutation; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; PTEN Phosphohydrolase; Quinolines; Receptors, Estrogen; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2011 |
Antitumor activity of NVP-BKM120--a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells.
Topics: Aminopyridines; Animals; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Cycle; Cell Proliferation; Enzyme Inhibitors; Fluorescent Antibody Technique; Glioma; Humans; Immunoenzyme Techniques; Mice; Mice, Nude; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Real-Time Polymerase Chain Reaction; RNA, Messenger; Tissue Distribution; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2012 |
NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations.
Topics: Aminopyridines; Cell Growth Processes; Cell Line, Tumor; Drug Synergism; Enzyme Inhibitors; Genes, ras; Humans; Morpholines; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; STAT3 Transcription Factor; Stomach Neoplasms; Tyrphostins | 2012 |
Phosphatidylinositide-3-kinase inhibitors: addressing questions of isoform selectivity and pharmacodynamic/predictive biomarkers in early clinical trials.
Topics: Aminopyridines; Female; Humans; Male; Morpholines; Neoplasms; Phosphoinositide-3 Kinase Inhibitors | 2012 |
Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.
Topics: Administration, Oral; Aminopyridines; Animals; Biological Availability; Blotting, Western; Cell Line, Tumor; Dose-Response Relationship, Drug; HCT116 Cells; HT29 Cells; Humans; Isoenzymes; Mice; Mice, Nude; Models, Molecular; Molecular Structure; Morpholines; Mutation; Neoplasms; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Rats; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dexamethasone; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Humans; Mice; Mice, SCID; Morpholines; Multiple Myeloma | 2012 |
An animal model of MYC-driven medulloblastoma.
Topics: Aminopyridines; Animals; Cell Proliferation; Cell Transformation, Neoplastic; Cerebellar Neoplasms; Cerebellum; Disease Models, Animal; Gene Expression Regulation, Neoplastic; Genes, p53; Imidazoles; Medulloblastoma; Mice; Morpholines; Neural Stem Cells; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Quinolines; TOR Serine-Threonine Kinases | 2012 |
Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Caspase 3; Cell Cycle Checkpoints; Cell Survival; Dose-Response Relationship, Drug; Gastrointestinal Neoplasms; HCT116 Cells; HT29 Cells; Humans; Imidazoles; Irinotecan; Morpholines; Mutation; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinolines; Signal Transduction; TOR Serine-Threonine Kinases | 2012 |
Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations.
Topics: Aminopyridines; Animals; Cell Cycle Checkpoints; Cell Line, Tumor; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Mice; Mitosis; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Protein Multimerization; Rats; Sulfonamides; Tubulin | 2012 |
3D tumour spheroids as a model to assess the suitability of [18F]FDG-PET as an early indicator of response to PI3K inhibition.
Topics: Aminopyridines; Animals; Biological Transport; Cell Line, Tumor; Cell Proliferation; Feasibility Studies; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Mice; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Phosphoproteins; Positron-Emission Tomography; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinolines; Spheroids, Cellular; Time Factors; Treatment Outcome | 2012 |
Secretin receptor promotes the proliferation of endocrine tumor cells via the PI3K/AKT pathway.
Topics: Adrenal Gland Neoplasms; Adrenal Glands; Adult; Aged; Aminopyridines; Animals; Apoptosis; Cell Proliferation; Cell Survival; Female; Gastrointestinal Agents; Gene Knockdown Techniques; Humans; Imidazoles; Male; Morpholines; Neurites; PC12 Cells; Pheochromocytoma; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinolines; Rats; Receptors, G-Protein-Coupled; Receptors, Gastrointestinal Hormone; RNA Interference; Secretin; Signal Transduction; Transcription, Genetic | 2012 |
The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Culture Media, Serum-Free; Drug Synergism; Everolimus; G1 Phase; Gene Expression Regulation, Neoplastic; Humans; Immunosuppressive Agents; Lung Neoplasms; Male; Mice; Mice, Nude; Morpholines; Neoplasm Proteins; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Recombinant Fusion Proteins; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2012 |
The phosphatidylinositol-3 kinase I inhibitor BKM120 induces cell death in B-chronic lymphocytic leukemia cells in vitro.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Agents; Apoptosis; Blotting, Western; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Treatment Outcome; Tumor Cells, Cultured | 2013 |
Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention.
Topics: Aminopyridines; Androgen Receptor Antagonists; Animals; Antineoplastic Agents; Benzamides; Benzimidazoles; Castration; Imidazoles; Male; MAP Kinase Kinase Kinases; Mice; Mice, Transgenic; Morpholines; Nitriles; Phenylthiohydantoin; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinolines; Testosterone | 2013 |
PAK1 mediates resistance to PI3K inhibition in lymphomas.
Topics: Aminopyridines; Biomarkers, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Gene Expression Profiling; Humans; Imidazoles; Lymphoma; Morpholines; Oligonucleotide Array Sequence Analysis; p21-Activated Kinases; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Small Molecule Libraries; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2013 |
Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
Topics: Aminopyridines; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Everolimus; Humans; Imidazoles; Indoles; Kidney Neoplasms; Liver Neoplasms; Mechanistic Target of Rapamycin Complex 1; Morpholines; Multiprotein Complexes; Niacinamide; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Pyrroles; Quinolines; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases | 2013 |
Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma.
Topics: Aminopyridines; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Camptothecin; Carcinoma, Hepatocellular; Cell Cycle; Cell Line; Cell Respiration; Cisplatin; Doxorubicin; Everolimus; Humans; Imidazoles; Immunoblotting; Immunohistochemistry; In Situ Nick-End Labeling; Irinotecan; Liver Neoplasms; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Quinolines; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
The PI3 kinase inhibitor NVP-BKM120 induces GSK3/FBXW7-dependent Mcl-1 degradation, contributing to induction of apoptosis and enhancement of TRAIL-induced apoptosis.
Topics: Aminopyridines; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; Down-Regulation; Drug Synergism; F-Box Proteins; F-Box-WD Repeat-Containing Protein 7; Glycogen Synthase Kinase 3; HCT116 Cells; Humans; Lung Neoplasms; Morpholines; Myeloid Cell Leukemia Sequence 1 Protein; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Recombinant Proteins; TNF-Related Apoptosis-Inducing Ligand; Ubiquitin-Protein Ligases | 2013 |
RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; MCF-7 Cells; Mice; Mice, Nude; Molecular Targeted Therapy; Morpholines; Open Reading Frames; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinolines; Ribosomal Protein S6 Kinases, 90-kDa; Signal Transduction; Transcriptome; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Inhibition of pan-class I phosphatidyl-inositol-3-kinase by NVP-BKM120 effectively blocks proliferation and induces cell death in diffuse large B-cell lymphoma.
Topics: Aminopyridines; Apoptosis; Autophagy; bcl-X Protein; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Class I Phosphatidylinositol 3-Kinases; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Lymphoma, Large B-Cell, Diffuse; Morpholines; Myeloid Cell Leukemia Sequence 1 Protein; Protein Biosynthesis; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2014 |
Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chromones; Everolimus; Female; Humans; Imidazoles; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinolines; Signal Transduction; Sirolimus; Tamoxifen; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2013 |
The phosphatidylinositol-3-kinase inhibitor NVP-BKM120 overcomes resistance signals derived from microenvironment by regulating the Akt/FoxO3a/Bim axis in chronic lymphocytic leukemia cells.
Topics: Aged; Aged, 80 and over; Aminopyridines; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Cell Movement; Coculture Techniques; Drug Resistance, Neoplasm; Forkhead Box Protein O3; Forkhead Transcription Factors; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Proteins; Middle Aged; Morpholines; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins; Tumor Microenvironment | 2013 |
Nuclear PTEN controls DNA repair and sensitivity to genotoxic stress.
Topics: Active Transport, Cell Nucleus; Aminopyridines; Animals; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Line; Cell Line, Tumor; Cell Nucleus; Cisplatin; DNA Breaks, Double-Stranded; DNA Damage; DNA Repair; DNA-Binding Proteins; Doxorubicin; Enzyme Inhibitors; Female; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Morpholines; Neoplasm Transplantation; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Serine-Threonine Kinases; PTEN Phosphohydrolase; Sumoylation; Transplantation, Heterologous; Tumor Suppressor Proteins | 2013 |
Improvement in hereditary hemorrhagic telangiectasia after treatment with the phosphoinositide 3-kinase inhibitor BKM120.
Topics: Aminopyridines; Female; Humans; Middle Aged; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Telangiectasia, Hereditary Hemorrhagic; Treatment Outcome | 2014 |
Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities.
Topics: Aminopyridines; Animals; Biphenyl Compounds; Brain Neoplasms; Cell Line, Tumor; Enzyme Inhibitors; Glioblastoma; Hedgehog Proteins; Humans; Mice; Mice, Nude; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; PTEN Phosphohydrolase; Pyridines; Ribosomal Protein S6 Kinases; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
The gene dosage of class Ia PI3K dictates the development of PTEN hamartoma tumor syndrome.
Topics: Alleles; Aminopyridines; Animals; Breast Neoplasms; Class Ia Phosphatidylinositol 3-Kinase; Disease Models, Animal; Female; Gene Dosage; Genotype; Hamartoma Syndrome, Multiple; Mice; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Skin Neoplasms | 2013 |
Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia.
Topics: Aminopyridines; Antineoplastic Agents; Drug Synergism; Everolimus; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Lymphocytes; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Morpholines; Multiprotein Complexes; Naphthyridines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Cell Culture; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
Downregulation of IGFBP2 is associated with resistance to IGF1R therapy in rhabdomyosarcoma.
Topics: Aminopyridines; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor Binding Protein 2; Mice; Mice, SCID; Molecular Targeted Therapy; Morpholines; Pyrimidines; Receptor, IGF Type 1; Rhabdomyosarcoma; Treatment Failure; Xenograft Model Antitumor Assays | 2014 |
Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia.
Topics: Aminopyridines; Animals; Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Flow Cytometry; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Effects of PI3K inhibitor NVP-BKM120 on acquired resistance to gefitinib of human lung adenocarcinoma H1975 cells.
Topics: Adenocarcinoma; Aminopyridines; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gefitinib; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; Matrix Metalloproteinase 9; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; RNA, Messenger; Vascular Endothelial Growth Factor A | 2013 |
Cotargeting the PI3K and RAS pathways for the treatment of neuroendocrine tumors.
Topics: Aminopyridines; Animals; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Diphenylamine; Drug Synergism; Humans; Imidazoles; Male; Mice; Mitogen-Activated Protein Kinases; Morpholines; Neuroendocrine Tumors; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Quinolines; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells.
Topics: Aminopyridines; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Mice; Mice, Nude; Morpholines; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2014 |
Hsp90 inhibition enhances PI-3 kinase inhibition and radiosensitivity in glioblastoma.
Topics: Aminopyridines; Animals; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Proliferation; Flow Cytometry; Gene Expression Regulation, Neoplastic; Glioblastoma; HSP90 Heat-Shock Proteins; Humans; Mice; Mice, Nude; Morpholines; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Radiation Tolerance; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 2014 |
Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Carcinosarcoma; Class I Phosphatidylinositol 3-Kinases; Endometrial Neoplasms; Female; Humans; Mice; Mice, SCID; Morpholines; Mutation; Paclitaxel; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2014 |
Circulating tumor cells as a biomarker of response to treatment in patient-derived xenograft mouse models of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aminopyridines; Animals; Antigens, Neoplasm; Biomarkers; Cell Adhesion Molecules; DNA Mutational Analysis; DNA Primers; Epithelial Cell Adhesion Molecule; Fluorescent Antibody Technique; Humans; Mice; Microfluidic Analytical Techniques; Morpholines; Neoplastic Cells, Circulating; Pancreatic Neoplasms; Statistics, Nonparametric | 2014 |
Regulation of O2 consumption by the PI3K and mTOR pathways contributes to tumor hypoxia.
Topics: Aminopyridines; Animals; Cell Hypoxia; Cell Line, Tumor; HCT116 Cells; Humans; Imidazoles; Mice; Morpholines; Neoplasms; Oxygen Consumption; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinolines; Signal Transduction; Spheroids, Cellular; TOR Serine-Threonine Kinases | 2014 |
Endothelin A receptor antagonism enhances inhibitory effects of anti-ganglioside GD2 monoclonal antibody on invasiveness and viability of human osteosarcoma cells.
Topics: Aminopyridines; Antibodies, Monoclonal; Cell Line, Tumor; Cell Survival; Endothelin A Receptor Antagonists; Gangliosides; Humans; Morpholines; Neoplasm Invasiveness; Osteosarcoma; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors | 2014 |
Inhibition of phosphatidylinositol 3-kinase/AKT signaling by NVP-BKM120 promotes ABT-737-induced toxicity in a caspase-dependent manner through mitochondrial dysfunction and DNA damage response in established and primary cultured glioblastoma cells.
Topics: Aminopyridines; Antineoplastic Agents; Apoptosis Inducing Factor; Apoptosis Regulatory Proteins; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Bcl-2-Like Protein 11; Biphenyl Compounds; Caspase 3; Caspase 8; Caspases; Cell Death; Cell Line, Tumor; Chromosome Segregation; Cytochromes c; DNA Damage; Drug Synergism; Glioblastoma; Humans; Intracellular Signaling Peptides and Proteins; Membrane Potential, Mitochondrial; Membrane Proteins; Mitochondria; Mitochondrial Proteins; Morpholines; Nitrophenols; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Poly(ADP-ribose) Polymerases; Primary Cell Culture; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Sulfonamides | 2014 |
Inhibiting Tankyrases sensitizes KRAS-mutant cancer cells to MEK inhibitors via FGFR2 feedback signaling.
Topics: Acetamides; Aminopyridines; Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Synergism; Erlotinib Hydrochloride; Feedback, Physiological; Female; Humans; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Morpholines; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrimidinones; Quinazolines; ras Proteins; Receptor, Fibroblast Growth Factor, Type 2; Signal Transduction; Sulfonamides; Tankyrases; Thiazoles; Xenograft Model Antitumor Assays | 2014 |
Disruption of follicular dendritic cells-follicular lymphoma cross-talk by the pan-PI3K inhibitor BKM120 (Buparlisib).
Topics: Aminopyridines; Animals; Cell Adhesion; Cell Communication; Cell Line, Tumor; Cell Movement; Cell Survival; Chemokine CXCL12; Cluster Analysis; Dendritic Cells, Follicular; Disease Models, Animal; Extracellular Matrix; Gene Expression Profiling; Humans; Lymphoma, Follicular; Mice; Morpholines; Neovascularization, Pathologic; Phosphoinositide-3 Kinase Inhibitors; Receptors, CXCR4; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Laser diode thermal desorption atmospheric pressure chemical ionization tandem mass spectrometry applied for the ultra-fast quantitative analysis of BKM120 in human plasma.
Topics: Aminopyridines; Atmosphere; Atmospheric Pressure; Calibration; Chemistry, Pharmaceutical; Chromatography, Liquid; Humans; Lasers; Linear Models; Liquid-Liquid Extraction; Morpholines; Plasma; Quality Control; Reference Values; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Temperature; Time Factors | 2014 |
Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition.
Topics: Aminopyridines; Apoptosis; Breast Neoplasms; DNA-Binding Proteins; Female; Gene Knockdown Techniques; Heterocyclic Compounds, 3-Ring; Humans; MCF-7 Cells; Morpholines; Nuclear Proteins; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Phosphorylcholine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6 Kinases, 70-kDa; RNA, Small Interfering; Signal Transduction; Transcription Factors; Transfection | 2014 |
Targeting Phosphatidylinositide3-Kinase/Akt pathway by BKM120 for radiosensitization in hepatocellular carcinoma.
Topics: Aminopyridines; Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Radiation Tolerance; Random Allocation | 2014 |
Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Cell Adhesion; Cell Cycle; Cell Line; Cell Line, Tumor; Chemotaxis; Coculture Techniques; Drug Screening Assays, Antitumor; Female; Fibronectins; Humans; Mesenchymal Stem Cells; Mice; Mice, SCID; Morpholines; Multiple Myeloma; Neoplasm Invasiveness; Neoplasm Proteins; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Receptors, CXCR4; RNA Interference; RNA, Small Interfering; Waldenstrom Macroglobulinemia; Xenograft Model Antitumor Assays | 2014 |
In vitro multifaceted activities of a specific group of novel phosphatidylinositol 3-kinase inhibitors on hotspot mutant PIK3CA.
Topics: Aminopyridines; Antineoplastic Agents; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Humans; Imidazoles; Indazoles; Morpholines; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinolines; Sulfonamides; Triazines | 2014 |
Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma.
Topics: Aminopyridines; Cell Line, Tumor; Cell Proliferation; Chemokine CXCL12; Everolimus; Human Umbilical Vein Endothelial Cells; Humans; Imidazoles; Interleukin-4; Interleukin-6; Lymphoma, Mantle-Cell; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Transcriptome; Tumor Microenvironment | 2014 |
Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Benzimidazoles; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Disease Models, Animal; Drug Screening Assays, Antitumor; Drug Synergism; Erlotinib Hydrochloride; Humans; MAP Kinase Kinase Kinases; Mice, Transgenic; Morpholines; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines | 2015 |
PKD1 is downregulated in non-small cell lung cancer and mediates the feedback inhibition of mTORC1-S6K1 axis in response to phorbol ester.
Topics: Aminopyridines; Benzamides; Blotting, Western; Butadienes; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromones; Diphenylamine; Enzyme Activation; Humans; Mechanistic Target of Rapamycin Complex 1; Morpholines; Multiprotein Complexes; Nitriles; Phorbol Esters; Real-Time Polymerase Chain Reaction; Ribosomal Protein S6 Kinases, 70-kDa; TOR Serine-Threonine Kinases; TRPP Cation Channels | 2015 |
Treatment effect of buparlisib, cetuximab and irradiation in wild-type or PI3KCA-mutated head and neck cancer cell lines.
Topics: Aminopyridines; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cetuximab; Chemoradiotherapy; DNA Repair; Drug Resistance, Neoplasm; ErbB Receptors; Head and Neck Neoplasms; Humans; Mechanistic Target of Rapamycin Complex 2; Morpholines; Multiprotein Complexes; Phosphatidylinositol 3-Kinases; TOR Serine-Threonine Kinases | 2015 |
The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma.
Topics: Aminopyridines; Animals; Apoptosis; Blotting, Western; Bone Diseases; Cell Cycle; Cell Proliferation; Disease Models, Animal; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Humans; Mice; Mice, Inbred C57BL; Morpholines; Multiple Myeloma; Osteoclasts; Osteolysis; Phosphoinositide-3 Kinase Inhibitors; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2015 |
Bridging continual reassessment method for phase I clinical trials in different ethnic populations.
Topics: Adult; Aminopyridines; Antineoplastic Agents; Clinical Trials, Phase I as Topic; Computer Simulation; Dose-Response Relationship, Drug; Ethnicity; Humans; Maximum Tolerated Dose; Morpholines; Multicenter Studies as Topic; Neoplasms; Pharmacogenetics; Research Design | 2015 |
Mouse model to clarify ovarian clear-cell carcinoma.
Topics: Aminopyridines; Animals; Carcinoma; Class I Phosphatidylinositol 3-Kinases; Disease Models, Animal; DNA-Binding Proteins; Female; Humans; Mice; Morpholines; Nuclear Proteins; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Transcription Factors | 2015 |
MEL-18 loss mediates estrogen receptor-α downregulation and hormone independence.
Topics: Aminopyridines; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Cysteine Endopeptidases; Drug Resistance, Neoplasm; Endopeptidases; Estrogen Receptor alpha; Estrogens; Female; Humans; Kaplan-Meier Estimate; Mice; Morpholines; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Polycomb Repressive Complex 1; Progesterone; Proportional Hazards Models; Proteasome Endopeptidase Complex; Protein Processing, Post-Translational; Receptor, ErbB-2; Receptors, Progesterone; RNA, Messenger; RNA, Neoplasm; Sp1 Transcription Factor; Sumoylation; Tamoxifen; Triple Negative Breast Neoplasms; Tumor Suppressor Protein p53 | 2015 |
Arg⁹⁷² insulin receptor substrate-1 inhibits endothelial nitric oxide synthase expression in human endothelial cells by upregulating microRNA-155.
Topics: Adult; Aged; Aminopyridines; Cells, Cultured; Diabetes Mellitus; Enzyme Activation; Female; Human Umbilical Vein Endothelial Cells; Humans; Insulin Receptor Substrate Proteins; Insulin Resistance; Male; MicroRNAs; Middle Aged; Morpholines; Nitric Oxide; Nitric Oxide Synthase Type III; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Transfection | 2015 |
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations.
Topics: Aminopyridines; Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Disease Models, Animal; Epithelial-Mesenchymal Transition; Humans; Imidazoles; Lung Neoplasms; Morpholines; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinolines; Signal Transduction; Thiazoles; Xenograft Model Antitumor Assays | 2015 |
Combined treatment by octreotide and everolimus: Octreotide enhances inhibitory effect of everolimus in aggressive meningiomas.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents; Cell Cycle; Cell Survival; Drug Therapy, Combination; Everolimus; Female; Humans; Imidazoles; Male; Meningeal Neoplasms; Meningioma; Middle Aged; Morpholines; Neurofibromin 2; Octreotide; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinolines; Receptors, Somatostatin; Signal Transduction; TOR Serine-Threonine Kinases | 2015 |
NVP-BKM120 potentiates apoptosis in tumor necrosis factor-related apoptosis-inducing ligand-resistant glioma cell lines via upregulation of Noxa and death receptor 5.
Topics: Aminopyridines; Antineoplastic Agents; Apoptosis; Astrocytes; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Glioma; Humans; Morpholines; Proto-Oncogene Proteins c-bcl-2; Receptors, TNF-Related Apoptosis-Inducing Ligand; TNF-Related Apoptosis-Inducing Ligand; Up-Regulation | 2015 |
Molecular effects of the phosphatidylinositol-3-kinase inhibitor NVP-BKM120 on T and B-cell acute lymphoblastic leukaemia.
Topics: Aminopyridines; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Cell Survival; Dose-Response Relationship, Drug; G2 Phase Cell Cycle Checkpoints; Humans; Jurkat Cells; Molecular Targeted Therapy; Morpholines; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Signal Transduction | 2015 |
Comparative effect of two pan-class I PI3K inhibitors used as anticancer drugs on human T cell function.
Topics: Aminopyridines; Antineoplastic Agents; Apoptosis; Cell Culture Techniques; Cell Cycle; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gonanes; Humans; Interleukin-2; Jurkat Cells; Lymphocyte Activation; Morpholines; Phosphoinositide-3 Kinase Inhibitors; T-Lymphocytes; Th1 Cells; Th2 Cells | 2015 |
Predominant Activation of JAK/STAT3 Pathway by Interleukin-6 Is Implicated in Hepatocarcinogenesis.
Topics: Aminopyridines; Animals; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Cyclic S-Oxides; Disease Models, Animal; Enzyme Activation; Humans; Inflammation; Interleukin-6; Janus Kinases; Liver; Liver Neoplasms; Morpholines; Niclosamide; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Signal Transduction; STAT3 Transcription Factor; Zebrafish; Zebrafish Proteins | 2015 |
Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas.
Topics: Aminopyridines; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Class I Phosphatidylinositol 3-Kinases; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Mechanistic Target of Rapamycin Complex 1; Morpholines; Multiprotein Complexes; Mutation; Osteosarcoma; Phosphorylation; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyridones; Pyrimidines; Pyrimidinones; Pyrroles; Sarcoma; Signal Transduction; TOR Serine-Threonine Kinases | 2015 |
Activity of BKM120 and BEZ235 against Lymphoma Cells.
Topics: Aminopyridines; Antineoplastic Agents; Autophagy; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Humans; Imidazoles; Lymphoma, Non-Hodgkin; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Prognosis; Quinolines; Reactive Oxygen Species; Signal Transduction | 2015 |
A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Morpholines; Neoplasm Metastasis; Phosphoinositide-3 Kinase Inhibitors; Postmenopause; PTEN Phosphohydrolase; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2016 |
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.
Topics: Aminopyridines; Animals; Antibodies; Cell Line, Tumor; CTLA-4 Antigen; Drug Resistance, Neoplasm; Drug Synergism; Humans; Immunotherapy; Melanoma; Mice; Morpholines; Programmed Cell Death 1 Receptor; PTEN Phosphohydrolase; T-Lymphocytes | 2016 |
Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cells.
Topics: Aminopyridines; Animals; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Mice; Mice, Nude; Morpholines; Neoplastic Stem Cells; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Signal Transduction | 2015 |
The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia.
Topics: Adult; Aged; Aminopyridines; Animals; Blotting, Western; Cell Line, Tumor; Cell Survival; Class I Phosphatidylinositol 3-Kinases; Dose-Response Relationship, Drug; Female; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Male; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Middle Aged; Morpholines; Proto-Oncogene Proteins c-akt; Signal Transduction; Time Factors; TOR Serine-Threonine Kinases; U937 Cells; Xenograft Model Antitumor Assays | 2015 |
PI3K Inhibitor Improves PFS in BELLE-2 Trial.
Topics: Aminopyridines; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Congresses as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Morpholines; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Treatment Outcome | 2016 |
Targeting the PI3K signaling pathway in KRAS mutant colon cancer.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cetuximab; Colonic Neoplasms; Disease Models, Animal; Drug Synergism; Humans; Male; MAP Kinase Signaling System; Molecular Targeted Therapy; Morpholines; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; ras Proteins; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
[Effects of NVP-BKM120 on the triple-negative breast cancer cell].
Topics: Aminopyridines; Animals; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Mice; Mice, Inbred BALB C; Mice, Nude; Morpholines; Triple Negative Breast Neoplasms | 2015 |
BKM-120 (Buparlisib): A Phosphatidyl-Inositol-3 Kinase Inhibitor with Anti-Invasive Properties in Glioblastoma.
Topics: Aminopyridines; Animals; Blood-Brain Barrier; Brain Neoplasms; Cell Adhesion; Cell Culture Techniques; Cell Line, Tumor; Cell Movement; Cell Proliferation; Enzyme Inhibitors; Glioblastoma; Humans; Mice; Mice, Nude; Microtubules; Morpholines; Neoplasm Invasiveness; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Spheroids, Cellular; Transplantation, Heterologous; Vimentin | 2016 |
Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Drug Synergism; Female; Humans; Mice; Morpholines; Ovarian Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Xenograft Model Antitumor Assays | 2016 |
Endothelin‑1 induces oncostatin M expression in osteoarthritis osteoblasts by trans‑activating the oncostatin M gene promoter via Ets‑1.
Topics: Aminopyridines; Base Sequence; Binding Sites; Cells, Cultured; Endothelin-1; Genes, Reporter; Humans; Molecular Sequence Data; Morpholines; Oligopeptides; Oncostatin M; Osteoarthritis; Osteoblasts; Peptides, Cyclic; Piperidines; Promoter Regions, Genetic; Protein Binding; Proto-Oncogene Protein c-ets-1; RNA Interference; RNA, Messenger; RNA, Small Interfering; Transcriptional Activation | 2016 |
PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Cell Line, Tumor; Cerebellar Neoplasms; Drug Resistance, Neoplasm; Fucosyltransferases; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; Medulloblastoma; Mice; Mice, Transgenic; Microarray Analysis; Molecular Targeted Therapy; Morpholines; NADH Dehydrogenase; Neoplasm Transplantation; Neoplastic Stem Cells; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; PTEN Phosphohydrolase; Signal Transduction; Stereotaxic Techniques; Xenograft Model Antitumor Assays | 2016 |
PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Evaluation, Preclinical; Drug Synergism; Female; Humans; Imidazoles; Leiomyosarcoma; Mice, Inbred NOD; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinolines; Reproducibility of Results; TOR Serine-Threonine Kinases | 2016 |
Differential Effects of PI3K and Dual PI3K/mTOR Inhibition in Rat Prolactin-Secreting Pituitary Tumors.
Topics: Aminopyridines; Animals; Cell Cycle Proteins; Cell Proliferation; Cell Survival; Humans; Imidazoles; Morpholines; Phosphatidylinositol 3-Kinases; Phosphorylation; Pituitary Neoplasms; Prolactin; Proto-Oncogene Proteins c-akt; Quinolines; Rats; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.
Topics: Aminopyridines; AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Animals; Cell Line, Tumor; Female; Humans; Indoles; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Morpholines; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein Serine-Threonine Kinases; Signal Transduction; Small Cell Lung Carcinoma; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2016 |
Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations.
Topics: A549 Cells; Aminopyridines; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Humans; Lung Neoplasms; MAP Kinase Signaling System; Morpholines; Mutation; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Signal Transduction | 2016 |
The combination of NVP-BKM120 with trastuzumab or RAD001 synergistically inhibits the growth of breast cancer stem cells in vivo.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; MCF-7 Cells; Mice; Mice, Nude; Morpholines; Neoplastic Stem Cells; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Signal Transduction; Trastuzumab; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2016 |
Differential effects of inhibitors of the PI3K/mTOR pathway on the expansion and functionality of regulatory T cells.
Topics: Aminopyridines; Antineoplastic Agents; Blotting, Western; Cell Proliferation; Cells, Cultured; Cytokines; Everolimus; Flow Cytometry; Humans; Imidazoles; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinolines; Signal Transduction; Sirolimus; T-Lymphocytes, Regulatory; TOR Serine-Threonine Kinases | 2016 |
Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases.
Topics: Adaptor Proteins, Signal Transducing; Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Breast Neoplasms; Carrier Proteins; Caspase 3; Cell Cycle Proteins; DNA Repair; Drug Resistance, Neoplasm; Drug Therapy, Combination; Eukaryotic Initiation Factors; Everolimus; Female; Gene Expression Profiling; Genomic Instability; Humans; Immunohistochemistry; Ki-67 Antigen; Magnetic Resonance Imaging; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, SCID; Molecular Targeted Therapy; Morpholines; Multiprotein Complexes; Neoplasm Transplantation; Phosphoinositide-3 Kinase Inhibitors; Phosphoproteins; Phosphorylation; Receptor, ErbB-2; Remission Induction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2016 |
Treatment with the PI3K inhibitor buparlisib (NVP-BKM120) suppresses the growth of established patient-derived GBM xenografts and prolongs survival in nude rats.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Glioblastoma; Humans; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt; Rats, Nude; Survival Analysis; Xenograft Model Antitumor Assays | 2016 |
[Phosphatidylinositide 3-kinase inhibitor BKM120 suppresses proliferation and promotes apoptosis of U251 glioblastoma cells].
Topics: Aminopyridines; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Flow Cytometry; Glioblastoma; Humans; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2 | 2016 |
PI3 Kinase Pathway Mutations in Human Cancers.
Topics: Aminopyridines; Class I Phosphatidylinositol 3-Kinases; Humans; Isoquinolines; Molecular Targeted Therapy; Morpholines; Mutation; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Purines; Quinazolinones; Signal Transduction; Tumor Suppressor Protein p53 | 2016 |
Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; DNA Damage; DNA, Neoplasm; Female; Humans; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Morpholines; Nucleosides; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Poly(ADP-ribose) Polymerase Inhibitors; Triple Negative Breast Neoplasms | 2016 |
Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Drug Synergism; Female; Genes, BRCA1; Genes, BRCA2; Humans; Middle Aged; Morpholines; Ovarian Neoplasms; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors | 2016 |
Novel phosphatidylinositol 3-kinase inhibitor BKM120 enhances the sensitivity of multiple myeloma to bortezomib and overcomes resistance.
Topics: Aminopyridines; Animals; Apoptosis; Bortezomib; Cell Cycle; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Humans; Inhibitory Concentration 50; Mice; Morpholines; Multiple Myeloma; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2017 |
Combination of phosphotidylinositol-3-kinase targeting with cetuximab and irradiation: A preclinical study on an orthotopic xenograft model of head and neck cancer.
Topics: Aminopyridines; Animals; Antineoplastic Agents, Immunological; Carcinoma, Squamous Cell; Cetuximab; Combined Modality Therapy; Disease Models, Animal; Female; Head and Neck Neoplasms; Mice; Mice, Nude; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays | 2017 |
[Molecular mechanisms of resistance to phosphatidyl inositol 3-kinase inhibitors in triple-negative breast cancer cells].
Topics: Adaptor Proteins, Signal Transducing; Aminopyridines; Animals; beta Catenin; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Imidazoles; Mice; Morpholines; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phosphoproteins; Proto-Oncogene Proteins c-akt; Quinolines; Signal Transduction; TOR Serine-Threonine Kinases; Triple Negative Breast Neoplasms | 2016 |
Blockade efficacy of MEK/ERK-dependent autophagy enhances PI3K/Akt inhibitor NVP-BKM120's therapeutic effectiveness in lung cancer cells.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chloroquine; Enzyme Inhibitors; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mice; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Xenograft Model Antitumor Assays | 2016 |
Inhibitor of pan class-I PI3K induces differentially apoptotic pathways in acute leukemia cells: Shedding new light on NVP-BKM120 mechanism of action.
Topics: Aminopyridines; Apoptosis; Cell Cycle; Cell Proliferation; Cell Survival; Enzyme Inhibitors; Humans; Leukemia; Morpholines; NF-kappa B; Phosphoinositide-3 Kinase Inhibitors; Signal Transduction; Tumor Suppressor Protein p53 | 2016 |
PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Crizotinib; Drug Synergism; Female; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mice; Mice, Nude; Microtubules; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Pleural Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Signal Transduction; Xenograft Model Antitumor Assays | 2016 |
Addition of the p110α inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer.
Topics: Aminopyridines; Animals; Antibodies; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Humans; Lapatinib; Mice; Morpholines; ortho-Aminobenzoates; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; PTEN Phosphohydrolase; Pyrimidinones; Quinazolines; Receptor, ErbB-2; Thiazoles; Xenograft Model Antitumor Assays | 2016 |
Targeting of PI3K/AKT/mTOR pathway to inhibit T cell activation and prevent graft-versus-host disease development.
Topics: Aminopyridines; Animals; Cell Proliferation; Graft vs Host Disease; Imidazoles; Lymphocyte Activation; Mice; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinolines; Signal Transduction; T-Lymphocytes; TOR Serine-Threonine Kinases | 2016 |
Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Benzimidazoles; Biomarkers; Body Weight; Cachexia; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Humans; Mice; Mitogen-Activated Protein Kinase Kinases; Morpholines; Muscle, Skeletal; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Xenograft Model Antitumor Assays | 2017 |
Highlights in Head and Neck Cancer.
Topics: Aminopyridines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemoradiotherapy; Clinical Trials as Topic; Enzyme Inhibitors; Head and Neck Neoplasms; Humans; Molecular Targeted Therapy; Morpholines; Nasopharyngeal Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Programmed Cell Death 1 Receptor; Squamous Cell Carcinoma of Head and Neck | 2017 |
Benefit Mixed with Caution for Buparlisib.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Morpholines; Postmenopause; Protein Kinase Inhibitors; Survival Analysis; Treatment Outcome | 2017 |
Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Everolimus; Extracellular Signal-Regulated MAP Kinases; Humans; Imidazoles; Leiomyosarcoma; MAP Kinase Kinase Kinases; Mechanistic Target of Rapamycin Complex 2; Mice; Morpholines; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridones; Pyrimidinones; Quinolines; Rapamycin-Insensitive Companion of mTOR Protein; RNA Interference; Signal Transduction; Time Factors; TOR Serine-Threonine Kinases; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Subcellular localization of FOXO3a as a potential biomarker of response to combined treatment with inhibitors of PI3K and autophagy in PIK3CA-mutant cancer cells.
Topics: 14-3-3 Proteins; Active Transport, Cell Nucleus; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Biomarkers, Tumor; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Cytoplasm; Dose-Response Relationship, Drug; Female; Forkhead Box Protein O3; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Hydroxychloroquine; Morpholines; Mutation; Protein Kinase Inhibitors; RNA Interference; Signal Transduction; Time Factors; Transfection; Uterine Cervical Neoplasms | 2017 |
A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Humans; Mice, Nude; Molecular Targeted Therapy; Morpholines; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Receptors, Fibroblast Growth Factor; RNA Interference; Signal Transduction; Time Factors; Transfection; Tumor Burden; Urinary Bladder Neoplasms; Urothelium; Xenograft Model Antitumor Assays | 2017 |
PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Mice; Morpholines; Mutation; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 2; Sulfonamides; Thiazoles; Xenograft Model Antitumor Assays | 2017 |
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Cytoprotection; Drug Resistance, Neoplasm; Drug Synergism; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Mice; Morpholines; Proto-Oncogene Proteins c-akt; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2017 |
Buparlisib-and the continued quest for the ideal cure.
Topics: Aminopyridines; Morpholines | 2017 |
Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention.
Topics: Aminopyridines; Cell Line, Tumor; Cell Proliferation; Cell Survival; Crystallography, X-Ray; HCT116 Cells; Humans; Molecular Structure; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Tubulin; Tubulin Modulators | 2017 |
BKM120 induces apoptosis and inhibits tumor growth in medulloblastoma.
Topics: Aminopyridines; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Humans; Medulloblastoma; Mice; Morpholines; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; RNA, Neoplasm; Survival Analysis; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2017 |
5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.
Topics: Administration, Oral; Aminopyridines; Animals; Antineoplastic Agents; Brain; Cell Proliferation; Dogs; Humans; Mice; Models, Molecular; Morpholines; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Rats; Rats, Nude; Signal Transduction; TOR Serine-Threonine Kinases | 2017 |
Novel pan PI3K inhibitor-induced apoptosis in APL cells correlates with suppression of telomerase: An emerging mechanism of action of BKM120.
Topics: Aminopyridines; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA; Enzyme Activation; Enzyme Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Morpholines; NF-kappa B; Phosphoinositide-3 Kinase Inhibitors; S Phase; Signal Transduction; Telomerase | 2017 |
Targeting Phosphatidylinositol 3-Kinase Signaling Pathway for Therapeutic Enhancement of Vascular-Targeted Photodynamic Therapy.
Topics: Aminopyridines; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Endothelial Cells; Humans; Imidazoles; Mice; Morpholines; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Recurrence, Local; Neoplasms; Neovascularization, Pathologic; Oxidative Stress; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Photochemotherapy; Porphyrins; Protein Kinase Inhibitors; Quinolines; Signal Transduction; Thiazoles; Verteporfin; Xenograft Model Antitumor Assays | 2017 |
Informed Consent and Decision Making Among Participants in Novel-Design Phase I Oncology Trials.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase I as Topic; Decision Making; Female; Humans; Informed Consent; Morpholines; Motivation; Neoplasm Metastasis; Protein Kinase Inhibitors; Qualitative Research; Research Subjects | 2017 |
Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen.
Topics: Aminopyridines; Antineoplastic Agents, Hormonal; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Estrogen Receptor alpha; Female; Humans; Morpholines; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptors, Estrogen; Signal Transduction; Tamoxifen; Thiazoles | 2017 |
PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Cell Line, Tumor; Cell Proliferation; CRISPR-Cas Systems; Drug Resistance, Neoplasm; Endometrial Neoplasms; Endometrium; Female; Humans; Mice; Mice, Transgenic; Morpholines; Neoplasms, Experimental; Phosphoinositide-3 Kinase Inhibitors; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Recombinational DNA Repair; Spheroids, Cellular | 2018 |
ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
Topics: Aminopyridines; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Autocrine Communication; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Female; Head and Neck Neoplasms; Humans; Interleukin-6; MAP Kinase Signaling System; Mice; Mice, Inbred NOD; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Receptors, Interleukin-6; RNA, Small Interfering; Squamous Cell Carcinoma of Head and Neck; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2018 |
Anti-tumor effects of NVP-BKM120 alone or in combination with MEK162 in biliary tract cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biliary Tract Neoplasms; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Drug Synergism; Humans; MAP Kinase Signaling System; Morpholines; Phosphatidylinositol 3-Kinases; raf Kinases; ras Proteins; Signal Transduction | 2017 |
Efficacy of buparlisib in treating breast cancer.
Topics: Aminopyridines; Breast Neoplasms; Clinical Trials as Topic; Female; Half-Life; Humans; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; TOR Serine-Threonine Kinases | 2017 |
An exploratory open-label, investigator-initiated study to evaluate the efficacy and safety of combination sonidegib and buparlisib for advanced basal cell carcinomas.
Topics: Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Carcinoma, Basal Cell; Cohort Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Prospective Studies; Pyridines; Skin Neoplasms; Survival Analysis; Treatment Outcome | 2018 |
Synergistic Antitumor Effect of BKM120 with Prima-1Met Via Inhibiting PI3K/AKT/mTOR and CPSF4/hTERT Signaling and Reactivating Mutant P53.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cleavage And Polyadenylation Specificity Factor; Cyclin-Dependent Kinase Inhibitor p21; Down-Regulation; Female; Humans; Mice; Mice, Nude; Morpholines; Proto-Oncogene Proteins c-akt; Quinuclidines; Signal Transduction; Thyroid Neoplasms; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53; Up-Regulation | 2018 |
Pan-class I PI3-kinase inhibitor BKM120 induces MEK1/2-dependent mitotic catastrophe in non-Hodgkin lymphoma leading to apoptosis or polyploidy determined by Bax/Bak and p53.
Topics: Aminopyridines; Apoptosis; bcl-2-Associated X Protein; Cell Cycle; Cell Death; Cell Line; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Cyclin B1; Flow Cytometry; Humans; Immunoblotting; Lymphoma, Non-Hodgkin; Mitosis; Morpholines; Phosphatidylinositol 3-Kinases; Polyploidy; Tumor Suppressor Protein p53 | 2018 |
Combined treatment with PI3K inhibitor BKM120 and PARP inhibitor olaparib is effective in inhibiting the gastric cancer cells with ARID1A deficiency.
Topics: Aminopyridines; Biomarkers, Tumor; Cell Line, Tumor; Chromatin Assembly and Disassembly; DNA Damage; DNA-Binding Proteins; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Morpholines; Nuclear Proteins; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Stomach Neoplasms; Transcription Factors | 2018 |
Buparlisib is a brain penetrable pan-PI3K inhibitor.
Topics: Administration, Oral; Aminopyridines; Animals; Blood-Brain Barrier; Brain; Female; Male; Mice; Morpholines; Phosphoinositide-3 Kinase Inhibitors | 2018 |
Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Enzyme Inhibitors; Everolimus; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Pituitary Neoplasms; Rats; Signal Transduction; Thiazoles | 2018 |
Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment.
Topics: Aminopyridines; Animals; Benzimidazoles; Camptothecin; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; HT29 Cells; Humans; Irinotecan; MAP Kinase Kinase 1; Mice; Molecular Targeted Therapy; Morpholines; Protein Kinase Inhibitors; Signal Transduction; Xenograft Model Antitumor Assays | 2018 |
PI3K blockage synergizes with PLK1 inhibition preventing endoreduplication and enhancing apoptosis in anaplastic thyroid cancer.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Drug Synergism; Endoreduplication; Humans; Mice; Morpholines; Neoplasms, Experimental; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms | 2018 |
JQ1 and PI3K inhibition synergistically reduce salivary adenoid cystic carcinoma malignancy by targeting the c-Myc and EGFR signaling pathways.
Topics: Aminopyridines; Apoptosis; Azepines; Carcinoma, Adenoid Cystic; Cell Cycle Proteins; Cell Proliferation; Cell Survival; Drug Synergism; Drug Therapy, Combination; ErbB Receptors; Gene Expression; Humans; Molecular Targeted Therapy; Morpholines; Nuclear Proteins; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Salivary Gland Neoplasms; Signal Transduction; Transcription Factors; Triazoles; Tumor Cells, Cultured | 2019 |
Antitumor effects and mechanisms of olaparib in combination with carboplatin and BKM120 on human triple‑negative breast cancer cells.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA End-Joining Repair; DNA Repair; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Morpholines; Phthalazines; Piperazines; Triple Negative Breast Neoplasms | 2018 |
Inhibition of PI3K signaling pathway enhances the chemosensitivity of APL cells to ATO: Proposing novel therapeutic potential for BKM120.
Topics: Aminopyridines; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Caspase 3; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; Drug Interactions; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; Intracellular Space; Leukemia, Promyelocytic, Acute; Morpholines; Phosphatidylinositol 3-Kinases; Reactive Oxygen Species; Signal Transduction | 2018 |
PI3K: A master regulator of brain metastasis-promoting macrophages/microglia.
Topics: Adult; Aged; Aminopyridines; Animals; Brain Neoplasms; Breast Neoplasms; Calcium-Binding Proteins; Disease Models, Animal; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Glial Fibrillary Acidic Protein; Humans; Macrophages; Mice; Mice, Inbred BALB C; Microfilament Proteins; Microglia; Middle Aged; Morpholines; Phosphatidylinositol 3-Kinases; Signal Transduction; TOR Serine-Threonine Kinases | 2018 |
Anticancer effect of pan-PI3K inhibitor on multiple myeloma cells: Shedding new light on the mechanisms involved in BKM120 resistance.
Topics: Aminopyridines; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Enzyme Inhibitors; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Humans; M Phase Cell Cycle Checkpoints; Morpholines; Multiple Myeloma; Phosphoinositide-3 Kinase Inhibitors; Tumor Protein p73 | 2019 |
The mechanistic links between insulin and human organic anion transporter 4.
Topics: Aminopyridines; Animals; Chlorocebus aethiops; COS Cells; Gene Knockdown Techniques; Humans; Immediate-Early Proteins; Insulin; Morpholines; Nedd4 Ubiquitin Protein Ligases; Organic Anion Transporters, Sodium-Independent; Phosphoinositide-3 Kinase Inhibitors; Protein Serine-Threonine Kinases; RNA, Small Interfering; Wortmannin | 2019 |
Therapeutic potential of nvp-bkm120 in human osteosarcomas cells.
Topics: Aminopyridines; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Caspase 3; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Humans; Morpholines; Osteosarcoma; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction | 2019 |
PI3K inhibitor provides durable response in metastatic metaplastic carcinoma of the breast: A hidden gem in the BELLE-4 study.
Topics: Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Female; Humans; Metaplasia; Morpholines; Paclitaxel; Phosphoinositide-3 Kinase Inhibitors; Randomized Controlled Trials as Topic; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
EGFR-mediated signaling pathway influences the sensitivity of oral squamous cell carcinoma to JQ1.
Topics: Aminopyridines; Analysis of Variance; Animals; Antineoplastic Agents; Apoptosis; Azepines; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Epidermal Growth Factor; ErbB Receptors; Female; Gene Knockdown Techniques; Humans; Mice; Morpholines; Mouth Neoplasms; Nuclear Proteins; Phosphoinositide-3 Kinase Inhibitors; Signal Transduction; Transcription Factors; Triazoles; Xenograft Model Antitumor Assays | 2018 |
Buparlisib is a novel inhibitor of daunorubicin reduction mediated by aldo-keto reductase 1C3.
Topics: Aldo-Keto Reductase Family 1 Member C3; Aldo-Keto Reductases; Aminopyridines; Binding Sites; Catalytic Domain; Daunorubicin; HCT116 Cells; Humans; Inhibitory Concentration 50; Kinetics; Molecular Docking Simulation; Morpholines; Recombinant Proteins | 2019 |
A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600
Topics: Aminopyridines; Disease Progression; Humans; Melanoma; Morpholines; Mutation; Proto-Oncogene Proteins B-raf; Vemurafenib | 2019 |
Micellar Formulation of Talazoparib and Buparlisib for Enhanced DNA Damage in Breast Cancer Chemoradiotherapy.
Topics: Aminopyridines; Animals; Breast Neoplasms; Cell Line, Tumor; Chemoradiotherapy; DNA Damage; Female; Humans; Mice; Mice, Inbred BALB C; Micelles; Morpholines; Phthalazines; Xenograft Model Antitumor Assays | 2019 |
The PI3K inhibitor buparlisib suppresses osteoclast formation and tumour cell growth in bone metastasis of lung cancer, as evidenced by multimodality molecular imaging.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Bone and Bones; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Molecular Imaging; Morpholines; Osteoclasts; Positron Emission Tomography Computed Tomography; Single Photon Emission Computed Tomography Computed Tomography; Treatment Outcome; X-Ray Microtomography | 2019 |
ERK-dependent IL-6 positive feedback loop mediates resistance against a combined treatment using danusertib and BKM120 in Burkitt lymphoma cell lines.
Topics: Aminopyridines; Benzamides; Burkitt Lymphoma; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Interleukin-6; Morpholines; Protein Kinase Inhibitors; Pyrazoles; Signal Transduction | 2019 |
Binimetinib, a novel MEK1/2 inhibitor, exerts anti-leukemic effects under inactive status of PI3Kinase/Akt pathway.
Topics: Aminopyridines; Antineoplastic Agents; Apoptosis; Benzimidazoles; Cell Cycle; Cell Line, Tumor; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; G1 Phase; Gene Expression Regulation, Leukemic; Genes, ras; Humans; Leukemia; MAP Kinase Signaling System; Morpholines; Mutation; Neoplasm Proteins; Oncogene Protein p21(ras); Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Signal Transduction | 2019 |
Reply to 'The use of buparlisib as a radiosensitiser: What about toxicity?'
Topics: Aminopyridines; Humans; Lung Neoplasms; Morpholines; Tumor Hypoxia | 2019 |
The use of buparlisib as a radiosentisiser: What about toxicity?
Topics: Aminopyridines; Humans; Lung Neoplasms; Morpholines; Tumor Hypoxia | 2019 |
Effective Treatment of Metastatic Melanoma by Combining MAPK and PI3K Signaling Pathway Inhibitors.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Melanoma; Mice, Inbred NOD; Mice, SCID; Mitogen-Activated Protein Kinases; Morpholines; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Signal Transduction; Skin Neoplasms; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
Inhibition of PI3K pathway using BKM120 intensified the chemo-sensitivity of breast cancer cells to arsenic trioxide (ATO).
Topics: Aminopyridines; Anoikis; Antineoplastic Agents; Arsenic Trioxide; Cell Line; Cell Proliferation; DNA-Binding Proteins; Drug Combinations; Drug Synergism; Epithelial Cells; Female; Forkhead Transcription Factors; G1 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Morpholines; Phosphatidylinositol 3-Kinases; Phosphatidylserines; Signal Transduction; Survivin; Telomerase; Transcription Factors | 2019 |
High-throughput compound screen reveals mTOR inhibitors as potential therapeutics to reduce (auto)antibody production by human plasma cells.
Topics: Aminopyridines; Antibody Formation; Autoantibodies; Autoimmune Diseases; B-Lymphocytes; Cell Differentiation; Drug Discovery; High-Throughput Screening Assays; Humans; Lymphocyte Activation; Morpholines; Plasma Cells; Protein Kinase Inhibitors; Purines; Sirolimus; TOR Serine-Threonine Kinases | 2020 |
Analyses of FGFR3 and PIK3CA mutations in neuroblastomas and the effects of the corresponding inhibitors on neuroblastoma cell lines.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Survival; Child; Child, Preschool; Class I Phosphatidylinositol 3-Kinases; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Humans; Imidazoles; Infant; Infant, Newborn; Male; Morpholines; Mutation; Neuroblastoma; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Pyrazoles; Quinolines; Receptor, Fibroblast Growth Factor, Type 3 | 2019 |
Transcriptome analysis reveals overlap in fusion genes in a phase I clinical cohort of TNBC and HGSOC patients treated with buparlisib and olaparib.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Cystadenocarcinoma, Serous; Female; Forkhead Transcription Factors; Gene Expression Profiling; Gene Fusion; Humans; Middle Aged; Morpholines; Ovarian Neoplasms; Phthalazines; Piperazines; Repressor Proteins; RNA-Seq; Triple Negative Breast Neoplasms | 2020 |
Rationale for the advancement of PI3K pathway inhibitors for personalized chordoma therapy.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Cell Line, Tumor; Chordoma; Humans; Mice; Morpholines; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Precision Medicine; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases | 2020 |
Anti-leukemic effect of PI3K inhibition on chronic myeloid leukemia (CML) cells: shedding new light on the mitigating effect of c-Myc and autophagy on BKM120 cytotoxicity.
Topics: Aminopyridines; Antineoplastic Agents; Apoptosis; Autophagy; Cell Survival; G2 Phase Cell Cycle Checkpoints; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Morpholines; Phosphoinositide-3 Kinase Inhibitors | 2020 |
LC-MS/MS determination of buparlisib, a phosphoinositide 3 kinase inhibitor in rat plasma: Application to a pharmacokinetic study.
Topics: Administration, Oral; Aminopyridines; Animals; Chromatography, Liquid; Linear Models; Male; Morpholines; Rats; Rats, Wistar; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2020 |
PI3K Abrogation Using Pan-PI3K Inhibitor BKM120 Gives Rise to a Significant Anticancer Effect on AML-Derived KG-1 Cells by Inducing Apoptosis and G2/M Arrest
Topics: Aminopyridines; Antineoplastic Agents; Apoptosis; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; G2 Phase Cell Cycle Checkpoints; Humans; Leukemia, Myeloid, Acute; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Structure-Activity Relationship; Tumor Cells, Cultured; U937 Cells | 2020 |
Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer.
Topics: Afatinib; Aminopyridines; Animals; Biopsy; Carcinoma, Squamous Cell; Gene Amplification; Gene Regulatory Networks; Genetic Variation; Head and Neck Neoplasms; High-Throughput Nucleotide Sequencing; Humans; Methotrexate; Mice; Morpholines; Papillomavirus Infections; Patient-Specific Modeling; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Androgen receptor phosphorylation at serine 81 and serine 213 in castrate-resistant prostate cancer.
Topics: Aged; Aminopyridines; Androgen Receptor Antagonists; Benzamides; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Humans; Male; Morpholines; Nitriles; Phenylthiohydantoin; Phosphatidylinositol 3-Kinase; Phosphorylation; Prognosis; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Serine; Signal Transduction; Survival Rate | 2020 |
Cutaneous T-Cell Lymphoma PDX Drug Screening Platform Identifies Cooperation between Inhibitions of PI3Kα/δ and HDAC.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Circulating Tumor DNA; Class I Phosphatidylinositol 3-Kinases; Drug Synergism; Female; Gene Knockdown Techniques; High-Throughput Screening Assays; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Lymphoma, T-Cell, Cutaneous; Mice; Morpholines; Protein Kinase Inhibitors; Skin; Skin Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays | 2021 |
A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Female; Goserelin; Humans; Morpholines; Phosphatidylinositol 3-Kinases; Receptor, ErbB-2; Tamoxifen; Thiazoles | 2021 |
Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Female; Fulvestrant; Humans; Morpholines; Phosphatidylinositol 3-Kinases; Purines; Receptors, Estrogen; Thiazoles | 2021 |
Buparlisib modulates PD-L1 expression in head and neck squamous cell carcinoma cell lines.
Topics: Aminopyridines; Antineoplastic Agents, Immunological; B7-H1 Antigen; Cell Line, Tumor; Cell Proliferation; Cell Survival; Epithelial Cells; Gene Expression Regulation, Neoplastic; Humans; Morpholines; Phosphatidylinositol 3-Kinases; Programmed Cell Death 1 Receptor; Proto-Oncogene Proteins c-akt; Radiation, Nonionizing; Signal Transduction; TOR Serine-Threonine Kinases | 2020 |
Setting the Pick: Can PI3K Inhibitors Circumvent CDK4/6 Inhibitor Resistance?
Topics: Aminopyridines; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Goserelin; Humans; Morpholines; Phosphatidylinositol 3-Kinases; Tamoxifen; Thiazoles | 2021 |
Discovery of novel PARP/PI3K dual inhibitors with high efficiency against BRCA-proficient triple negative breast cancer.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Male; Mice; Mice, Inbred BALB C; Models, Molecular; Molecular Docking Simulation; Molecular Targeted Therapy; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein Binding; Solubility; Structure-Activity Relationship; Triple Negative Breast Neoplasms | 2021 |
PI3k inhibitors (BKM120 and BYL719) as radiosensitizers for head and neck squamous cell carcinoma during radiotherapy.
Topics: Aminopyridines; Carcinoma, Squamous Cell; Cell Line, Tumor; Head and Neck Neoplasms; Humans; Morpholines; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Radiation-Sensitizing Agents; Thiazoles | 2021 |
BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expression.
Topics: Aminopyridines; Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Cell Line, Tumor; DNA Repair Enzymes; Exodeoxyribonucleases; Female; Forkhead Box Protein M1; Gene Expression Regulation, Neoplastic; Humans; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Phthalazines; Piperazines; Triple Negative Breast Neoplasms | 2021 |
Vitamin C sensitizes triple negative breast cancer to PI3K inhibition therapy.
Topics: Aminopyridines; Animals; Apoptosis; Ascorbic Acid; Cell Line, Tumor; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Histone Code; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Precision Medicine; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2021 |
AP-2α Regulates S-Phase and Is a Marker for Sensitivity to PI3K Inhibitor Buparlisib in Colon Cancer.
Topics: Aminopyridines; Animals; Biomarkers, Tumor; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockout Techniques; HCT116 Cells; Humans; Mice; Morpholines; Phosphoinositide-3 Kinase Inhibitors; RNA Interference; RNA-Seq; S Phase; Transcription Factor AP-2; Xenograft Model Antitumor Assays | 2021 |
Synergistic effects of BKM120 and panobinostat on pre-B acute lymphoblastic cells: an emerging perspective for the simultaneous inhibition of PI3K and HDACs.
Topics: Aminopyridines; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Histone Deacetylases; Humans; Morpholines; Panobinostat; Phosphatidylinositol 3-Kinases | 2022 |
BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair.
Topics: Aminopyridines; Animals; Female; Glioblastoma; Humans; Indoles; Mice; Morpholines; Poly(ADP-ribose) Polymerase Inhibitors; Recombinational DNA Repair; Zebrafish | 2021 |
Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gain of Function Mutation; Humans; Mice, Nude; Molecular Docking Simulation; Molecular Dynamics Simulation; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Multimerization; Quinolines; Receptor, ErbB-2; Receptor, ErbB-3; Trastuzumab; Xenograft Model Antitumor Assays | 2021 |
Dual targeting of MEK and PI3K effectively controls the proliferation of human EGFR-TKI resistant non-small cell lung carcinoma cell lines with different genetic backgrounds.
Topics: Afatinib; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase Kinases; Morpholines; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Pyrrolidinones; Quinolines | 2021 |
Hydroxychloroquine synergizes with the PI3K inhibitor BKM120 to exhibit antitumor efficacy independent of autophagy.
Topics: Aminopyridines; Animals; Autophagy; Humans; Hydroxychloroquine; Mice; Mice, Nude; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Zebrafish | 2021 |
Dual Targeting by Inhibition of Phosphoinositide-3-Kinase and Mammalian Target of Rapamycin Attenuates the Neuroinflammatory Responses in Murine Hippocampal Cells and Seizures in C57BL/6 Mice.
Topics: Aminopyridines; Animals; Apoptosis; Cell Line; Cytokines; Hippocampus; Imidazoles; Immunosuppressive Agents; Male; Membrane Potential, Mitochondrial; Mice; Mice, Inbred C57BL; Morpholines; Neuroinflammatory Diseases; Oxidative Stress; Phosphoinositide-3 Kinase Inhibitors; Quinolines; Seizures; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2021 |
PI3K inhibition by BKM120 results in anti-proliferative effects on corticotroph tumor cells.
Topics: Adenoma; Adrenocorticotropic Hormone; Aminopyridines; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Corticotrophs; Humans; Mice; Morpholines; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; Proto-Oncogene Proteins c-akt | 2022 |
The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines.
Topics: Aminopyridines; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Heterocyclic Compounds, 3-Ring; Humans; Morpholines; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Signal Transduction | 2022 |
BKM120 alters the migration of doublecortin-positive cells in the dentate gyrus of mice.
Topics: Aminopyridines; Animals; Dentate Gyrus; Doublecortin Domain Proteins; Doublecortin Protein; Hippocampus; Humans; Mice; Microtubule-Associated Proteins; Morpholines; Neuropeptides; Proto-Oncogene Proteins c-akt | 2022 |
Preclinical and clinical evaluation of Buparlisib (BKM120) in recurrent/refractory Central Nervous System Lymphoma.
Topics: Aminopyridines; Central Nervous System; Chronic Disease; Humans; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Prospective Studies | 2023 |